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ABSTRACT
The placebo response can affect inference in analysis of data from clinical trials. It can bias
the estimate of the treatment effect, jeopardize the effort of all involved in a clinical trial
and ultimately deprive patients of potentially efficacious treatment. The Sequential Parallel
Comparison Design (SPCD) is one of the novel approaches addressing placebo response in
clinical trials. The analysis of SPCD clinical trial data typically involves classification of
subjects as ‘placebo responders’ or ‘placebo non-responders’. This classification is done
using a specific criterion and placebo response is treated as a measurable characteristic.
However, the use of criterion may lead to subject misclassification due to measurement
error or incorrect criterion selection. Subsequently, misclassification can directly affect
SPCD treatment effect estimate. We propose to view placebo response as an unknown
random characteristic that can be estimated based on information collected during the
trial. Two strategies are presented here. First strategy is to model placebo response using
criterion classification as a starting point or the observed data, and to include the placebo
response estimate into the treatment effect estimation. Second strategy is to jointly model
latent placebo response and the observed data, and estimate treatment effect from the joint
model. We evaluate both strategies on a wide range of simulated data scenarios in terms
of type I error control, mean squared error and power. We then evaluate the strategies
in presence of missing data and propose a method for missing data imputation under the
non-informative missingness assumption. The data from a recent SPCD clinical trial is
used to compare results of the proposed methods with reported results of the trial.
v
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Chapter 1
Background and Motivation
21.1 Placebo response
The placebo response is defined by The American Heritage Stedman’s Medical Dictionary
as a beneficial effect in a patient following a particular treatment that arises from the
patient’s expectations concerning the treatment rather than from the treatment itself. [1]
The placebo response can be observed in both subjects assigned placebo and subjects
assigned active drug. However, the extent and the mechanisms of placebo response in
placebo and active drug groups may differ, so that the placebo response may not be assumed
to have an additive effect.
Enck et al. [2] presented a literature review addressing the factors associated with
placebo response. The authors cited several meta-analyses evaluating association of the
baseline symptom severity and improvement in placebo and active drug groups. [3, 4] The
studies in both adults and children showed that improvement in placebo group was strongly
associated with the baseline symptom severity, however the baseline severity of symptoms
was not associated with improvement in the active drug group. Authors argued that if the
same factor affects improvement in placebo and in active drug groups differently, then the
response in these groups must be driven by different mechanisms.
There is still a debate about biological mechanisms of placebo response. The studies
suggest that placebo responsiveness depends on functioning of dopaminergic and opioid
systems. [5] Large placebo response is shown to be associated with greater dopamine and
opioid activity. Therefore, it is fair to hypothesize, that placebo response can be seen not
only as a characteristic that is either present or absent in an individual, but also as a
characteristic that can be present with a different degree.
1.2 Sequential Parallel Comparison Design
Accumulating empirical evidence suggests that, in some cases, the gold standard of re-
search, that is the classical double blinded randomized clinical trial, may be suboptimal in
presence of robust placebo responses. [2, 6, 7] The placebo response may lead to difficulties
3in estimation of the true effect size and ultimately may prevent effective compounds from
entering the market or existing drugs from new applications. As researchers struggle with
placebo response issue, the new trial designs are becoming available and new statistical
approaches are needed to analyze the data.
Screen
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Figure 1.1: Sequential Parallel Comparison Design
The Sequential Parallel Comparison Design or SPCD [6, 8–12] is one of the novel
approaches addressing placebo response. There are several variations of the SPCD, but
in general it is a two-stage of equal duration design comparing active drug and placebo
(Figure 1.1). At the beginning of Stage I subjects are randomized to receive either drug or
placebo, typically with more subjects assigned placebo, e.g. with 2:1 or 3:1 ratio. At the
end of the Stage I those who were assigned placebo are classified as ‘placebo responders’
4or ‘placebo non-responders’, based on their outcome. Then ‘placebo non-responders’ are
re-randomized to receive active drug or placebo during Stage II. Typically, those assigned
to active treatment at Stage I continue on the active treatment at Stage II and ‘placebo
responders’ continue on placebo or are re-randomized to active drug or placebo. The
overall treatment effect is a weighted average of Stage I estimate in full sample and Stage
II estimate in ‘placebo non-responders’. The SPCD is considered to be an enrichment
design [13] with the second stage of the trial focused on those subjects who did not respond
to placebo during the first stage. Despite of its novelty, there is already a large body of
statistical literature that deals with inference based on the SPCD data.
In general, for binary outcome data several methods were proposed to date: linear
combination test, Wald test, likelihood ratio test and variations of the score test. [6, 7,
14, 15] For continuous outcomes there are fewer choices which include, for example, use
of a seemingly unrelated regression (SUR) proposed by Tamura and Huang [16], and an
ordinary least squares (OLS) approach proposed by Chen et al. [17]. Both methods use
only part of the data collected during the trial, completely discarding Stage II data from
‘placebo responders’ and from Stage I active treatment subjects. Doros et al. [18] have
addressed the problem of underutilized data in context of continuous outcome analysis,
proposing to use a repeated measures model that allowed to include information from all
subjects into estimation of the drug effect.
1.3 Recent SPCD study example
Throughout the text we will be using data from a recent SPCD trial to apply the proposed
methodology to a specific example of clinical data. The trial, which we will refer to as
ADAPT-A trial, is described here.
The multi-center, double-blind placebo-controlled study of the efficacy of low-dose
aripiprazole (2 mg/day) adjunctive to antidepressant therapy (ADT) in the treatment
of major depressive disorder patients with a history of inadequate response to prior ADT
5(ADAPT-A) was conducted using SPCD. [19] After screening, patients were randomized to
either aripiprazole-aripiprazole (n = 54), placebo-placebo (n = 83) or placebo-aripiprazole
(n = 84) with a 2:3:3 ratio, according to format 2 of SPCD (therefore with a preran-
domization rather than a re-randomization).[6] The patients were followed for 60 days (30
days Stage I and 30 days Stage II), with efficacy evaluations performed every 10 days.
The key secondary endpoint was the difference in absolute change from baseline in the
Montgomery-Asberg Depression Rating Scale (MADRS) score between aripiprazole 2 mg
and placebo. The placebo non-response was defined at the end of Stage I as less than a
50% decrease in MADRS total score from baseline and a MADRS score greater than 16.
The summaries of the outcome are presented in Table 1.1.
Table 1.1: Baseline MADRS score and change for Stage I and Stage II
Time Measure Aripiprazole Placebo
Baseline N 54 167
Mean±SD 30.69±4.02 31.20±4.75
Stage I N 52 162
Mean±SD -8.46±7.18 -8.26±8.15
Stage II N 58 61
Mean±SD -5.84±6.98 -3.30±6.00
ADAPT-A data showed that Stage I outcome changes were either not significantly or
negatively correlated with Stage II changes. For aripiprazole-aripiprazole group Pearson
correlation was ρ = −0.32 (p = 0.027), for placebo-placebo group ρ = −0.08 (p = 0.503),
and for placebo-aripiprazole group ρ = −0.18 (p = 0.119).
1.4 Estimation of placebo response
The problem of placebo response estimation is central for SPCD studies. Since SPCD
treatment effect estimation is based on data from enrichment to ‘non-responders’, presence
of misclassification may lead to the bias in the estimated treatment effect.
6SPCD assumes that each subject is either ‘placebo responder’ or ‘placebo non-responder’
[6, 7, 14–18], which is determined based on the measurements performed during Stage I
of the trial. The response status is viewed as a characteristic defined for a specific trial
and a specific outcome measure. At the study design stage, investigators set a specific
rule or criterion for classification of subjects as either ‘placebo responders’ or ‘placebo non-
responders’. The rule is applied to classify subjects receiving placebo during Stage I and it
is often based on the percentage of improvement from baseline. For example, if the criterion
is set to 50% improvement, then a subject who improves by 55% is classified as ‘placebo
responder’, and a subject who improves by 45% is classified as ‘placebo non-responder’.
Several weaknesses of this criterion-based classification approach can be noted. First,
the cutoff point of the criterion is generally set according to expert knowledge, but may not
be necessarily correct. Second, the criterion implies truncation of the response measure
distribution. In the 50% improvement criterion example, subjects with 51% and 49%
improvement are classified differently even though the difference in improvement is trivial.
Third, in the criterion-based classification setting the measurement error can have a big
impact. In general, measurement error can play a big role in placebo response. Fava (2003)
states that the measurement error or, similarly, poor sensitivity of the instrument can be
a cause of observed placebo response.[6]
A small simulation study illustrates possible extent of misclassification based on one
of the scales widely used in psychiatric studies - the Montgomery-Asberg Depression Rat-
ing Scale (MADRS). MADRS has ten questions with possible score from 0 to 6 for each
question, and a total score ranging form 0 to 60. The higher scores correspond to worse
outcome. Assessors are given anchor point descriptions for scores 0, 2, 4 and 6, while scores
1, 3 and 5 are the mid-points.
We used data from the ADAPT-A trial to assess the criterion-based classification ap-
proach to placebo response in terms of its sensitivity to an error. To evaluate an impact
of the error associated with precision of the estimate, we generated 10,000 samples based
on the original data with added random error δ ∈ (−2,−1, 1, 2) at the error probability
7p(δ) ∈ (0.1, 0.2, 0.3). Then, to evaluate an impact of the error associated with accuracy of
the estimate, we varied the true classification threshold in all simulated samples from 20%
to 80% in 10% increments. The study classification criterion was set at 50% improvement
for all simulations.
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Figure 1.2: Extent of misclassification due to measurement error and bias
Figure 1.2 shows the possible extent of misclassification attributed to measurement
error (panel A) and to bias due to selection of incorrect criterion threshold (panel B). The
more prevalent and larger measurement errors lead to higher misclassification. Even bigger
potential contributor to misclassification is the response threshold bias. The magnitude of
possible misclassification due to the bias is ten fold the one due to the measurement error.
Note, that the majority of placebo subjects in ADAPT-A study improved less than 50%
of their baseline score (panel C). This causes the asymmetry of misclassification seen in
panel B.
8Table 1.2: Effect of criterion choice on SPCD Stage II treatment effect estimate
Criterion Non-Responders Responders Treatment Effect
Mean SD Mean SD Non-Responders
50% change -5.47 5.31 -19.34 6.73 -2.75 (SE=1.01)
48% change -5.38 5.25 -19.25 6.66 -2.84 (SE=1.01)
46% change -5.29 5.17 -19.16 6.59 -2.93 (SE=1.00)
44% change -5.21 5.12 -19.05 6.53 -3.02 (SE=1.00)
42% change -4.88 4.89 -18.62 6.36 -3.35 (SE=0.98)
40% change -4.44 4.55 -18.15 6.16 -3.79 (SE=0.96)
The effect of change in the criterion cutoff on estimate of the treatment effect in SPCD
is presented in Table 1.2. Using data from ADAPT-A trial, we changed the criterion cutoff
from 50% to 40% and calculated Stage II treatment effect using repeated measures model
approach. [18] The 10% change in cutoff resulted in one standard error change of the
treatment effect in this clinical trial.
In this dissertation, we propose two approaches addressing both precision and accu-
racy of the placebo response estimate and its incorporation in the evaluation of treatment
efficacy in the context of SPCD. Both approaches assume that placebo response is a char-
acteristic that it is not directly observable. We propose statistical methodology to estimate
this characteristic along with the appropriate uncertainty. The estimated values are then
incorporated into the analysis of efficacy of the treatment interventions. In the context
of the two approaches, we further study the performance of the proposed methodologies
in the presence of missing data. In the context of SPCD, missing data has an enhanced
damaging effect on the integrity of the analysis results, as dropout during the first stage
precludes the patient from being included in the analysis of the second stage. Therefore,
appropriate methods to reduce bias and increase power are needed.
The remaining of the dissertation reads as follows. In the second chapter we treat
placebo response (or, inversely, placebo non-response) as a continuous characteristic. The
9proposed methods estimate degree of response to placebo and allow to smooth transi-
tion from response to non-response. In the third chapter we treat placebo response/non-
response as a latent binary characteristic. This approach uses stochastic definition of
placebo response and performs classification based on the observed data likelihood. The
fourth chapter of the thesis is focused on a problem of missing data in SPCD setting. We
generalize the latent binary characteristic approach to include intermediate observations
and propose a strategy of SPCD treatment effect estimation based on observed and imputed
data. The final chapter summarizes our findings and outlines possible future studies.
Chapter 2
Placebo Response as Continuous Characteristic
11
2.1 Introduction
This chapter describes a new approach utilizing repeated measures model [18] that would
address possible misclassification of subjects as ‘placebo responders’ or ‘placebo non-
responders’ and include more subjects in the actual Stage II effect estimation.
Both, accurate classification and efficient use of the data are important in SPCD setting
due to selective use of the data collected during Stage II of the trial. The SPCD is con-
sidered to be an enrichment design [13] with the second stage of the trial focused on those
subjects who did not respond to placebo during the first stage. Therefore, the analyzable
sample decreases from the first stage to the second stage. This happens despite the fact
that some (or in some cases all) subjects are continuing the trial and the information is
being collected.
Several modifications of SPCD were proposed to date to address the efficiency of data
use. Ivanova and Tamura [20] proposed the two-way enriched design (TED) as a variation
of SPCD that to some extent addresses the issue of utilized information. They proposed in
the context of binary outcome measure to re-randomize those who responded to drug during
Stage I to drug and placebo (1:1) at Stage II and include this information into overall drug-
placebo comparison. Doros et al. [18] have addressed the problem of underutilized data
in context of continuous outcome analysis, proposing to use a repeated measures model
that allowed to include information from all subjects into estimation of the drug effect.
However, to our knowledge, there were no attempts to improve classification of subjects
with respect to their response to placebo in SPCD setting.
This chapter consists of three main parts. The first part presents methodological bases
for the proposed method and presents the model. The second part presents a large simula-
tion study comparing the proposed method performance to performance of the unweighted
repeated measures model. Finally, the third part of the chapter is an application of the
method to the data from an actual SPCD trial of antidepressant therapy - ADAPT-A
study. [19]
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2.2 Methodology
2.2.1 Repeated measures model approach
Doros et al. [18] proposed a repeated measures statistical model, which in contrast to the
previous strategies of analysis [16, 17] uses all available data collected during SPCD trial.
The model describes all collected data jointly with a series of equations. Information from
all subjects, even those not directly involved in the contrast of interest, and the covariance
of the measures across the stages of the trial are included into the drug effect estimation.
Figure 2.1 panel A shows graphical representation on the effects estimated with the
repeated measure model. The dashed arrows represent outcome progression in placebo
group and the solid arrows - in active treatment group. Placebo group’s overall change
in Stage I is δ0 from which the placebo non-responders differ by δ01 and placebo respon-
ders - by δ02. Active treatment group’s change in Stage I is δ0 + δ1. Stage I placebo
non-responders, re-randomized to placebo, change during Stage II by δ2. Placebo non-
responders, re-randomized to active treatment, change during Stage II by δ2 + δ3. Stage I
placebo responders, remaining on placebo during Stage II, change by δ4. Finally, Stage I
active treatment group remains on drug and changes during Stage II by δ5.
The parameter of interest δv = vδ1+(1− v)δ3, is the weighted average treatment effect
in all subjects in Stage I and in placebo non-responders in Stage II. The effect weight
v is specified at the beginning of the trial and can be optimized for a given treatment
allocation.[18] A test for H0 : δv = vδ1 + (1− v)δ3 = 0 is based on the test statistic
T =
vδˆ1 + (1− v)δˆ3√
v2V ar(δˆ1) + 2v(1 − v)Cov(δˆ1, δˆ3) + (1− v)2V ar(δˆ3)
,
where the effects, variances and covariances are estimated based on the model. Under the
null hypothesis H0, the above test statistic is assumed to approximately follow a standard
normal distribution.
We now propose a change in the method of analysis of SPCD trial data that will include
13
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Figure 2.1: Parametrization of SPCD
more subjects into the estimation of the Stage II effect by using all re-randomized Stage I
placebo subjects and the weighted estimation for the Stage II effect. This would hopefully
increase precision of the estimate and increase the test power.
2.2.2 Placebo non-response and new model for the data
The placebo response can be defined explicitly as the change in the outcome measure
from baseline in subjects treated with placebo. However, simple classification of subjects
as placebo responders or placebo non-responders based on this change is susceptible to
misclassification. In general, we want to define placebo response as a characteristic that is,
to some extent, present in each participant of the trial.
If that characteristic is known or measurable, we can scale it to range from 0 to 1 so that
scores close to 0 correspond to high placebo response and scores close to 1 correspond to
low placebo response. These can be seen as subject contributions (weights) in the placebo
response corrected analysis. We propose to use these weights for estimation of the placebo
response corrected treatment effect in Stage II of the SPCD in Stage I placebo subjects.
In previous approaches proposed by Tamura and Huang, and Chen et al., placebo non-
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responders are used to estimate treatment effect in Stage II while placebo responders are
excluded from the estimation, which is tantamount to assigning placebo non-responders a
weight of 1 and placebo responders a weight of 0 for the analysis of Stage II data. Thus,
the 0/1 classification can be seen as a particular case of this more general approach. Let’s
first assume that the non-response characteristic is known.
The proposed parametrization is presented on Figure 2.1 panel B. Both placebo re-
sponders and placebo non-responders are re-randomized after Stage I in a 1:1 ratio to active
treatment or placebo in Stage II. Therefore, the treatment effect in Stage II can be com-
puted in all Stage I placebo subjects. Figure 2.1 panel B notations are the same as Figure
2.1 panel A notations with one exception: the Stage II treatment effect can now be defined
in both placebo non-responders (indicated by δ31) and placebo responders (indicated by
δ32).
Let us suppose we analyze data from a 12 week SPCD trial. Both stages are of equal
length - Stage I is from baseline to Week 6 and Stage II is from Week 6 to Week 12. The
outcome for Stage I is defined as change from baseline to Week 6, and the outcome for
Stage II is defined as change from Week 6 to Week 12.
The Equations Under The Model: The full model can be specified with the three
following equations:
1. E(∆Yi1) = α01 + α11Yi1,0 + δ1Gi1; i = 1 : N,
2. E(∆Yi2) = α02 + α12Yi2,01 + δ3Gi2; i = 1 : nP ,
3. E(∆Yi2) = α03 + α13Yi2,02; i = nP + 1 : N.
The first equation relates the outcome at the end of Stage I (∆Yi1 = Yi6− Yi1,0) to the
outcome at baseline (Yi1,0) and the treatment assignment during Stage I (Gi1). It applies
to all N subjects in the trial. The second equation relates the outcome at the end of Stage
II (∆Yi2) to Stage II baseline (Yi2,01) and the new treatment assignment (Gi2) for the
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re-randomized Stage I placebo group (nP here is the number of Stage I placebo subjects).
Finally, the third equation relates the outcome at the end of Stage II to Stage II baseline
(Yi2,02) for subjects randomized to drug in Stage I.
The Covariance Under The Model: The errors ǫ under the model are distributed nor-
mally with mean E(ǫ) = 0 and variance V ar(ǫ) = σ2Σ, where σ2 is unknown and Σ is
defined as follows, reflecting correlation between Stage I and Stage II (ρ12):
Σi = wi
−1/2
 1 ρ12
ρ12 1
wi−1/2, i = 1 : nP Σi =
 1 ρ12
ρ12 1
 , i = nP + 1 : N
The weights are set to 1 for all subjects in Stage I. In Stage II all Stage I treatment
subjects are assigned a weight of 1, but Stage I placebo subjects are assigned weights based
on their non-response to placebo. Therefore, wi takes the following form:
wi =
 1 0
0 wi

In matrix form the model can be written as ∆Yi = Xiβ + ǫi, where ∆Yi is a vector of
outcome measures and Xi is the covariate matrix for individual i. The generalized least
squares estimate for vector of coefficients is βˆ =
{
N∑
i=1
(X ′iΣ
−1
i Xi)
}−1 N∑
i=1
X ′iΣ
−1
i ∆Yi. With
Σi known, the variance of the estimate Var(βˆ) = σ
2
{
N∑
i=1
(X ′iΣ
−1
i Xi)
}−1
. The estimate is
unbiased, and for a given wi both σ
2 and Σi are estimated from the data using restricted
maximum likelihood. To account for possible model mis-specification of the variance, the
‘Sandwich Estimator’ of the variance, a robust estimate of the variance, can be used:
V˜ar(βˆ) =
{
N∑
i=1
(X ′iΣ
−1
i Xi)
}−1 N∑
i=1
(X ′iΣ
−1
i ViΣ
−1
i Xi)
{
N∑
i=1
(X ′iΣ
−1
i Xi)
}−1
, where Vi = (∆Yi−
Xiβˆ)(∆Yi −Xiβˆ)′.
Therefore, we estimate the Stage I effect δˆ1, the Stage II effect δˆ3, with corresponding
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variances and covariance Var(δˆ1), Var(δˆ3) and Cov(δˆ1, δˆ3).
The Treatment Effect Esimate: The treatemnt effect is defined as a linear combination
of the Stage I effect δ1 and the Stage II effect δ3 estimated in all Stage I placebo subjects.
The SPCD effect weight v is specified. A test for H0 : δv = vδ1 + (1 − v)δ3 = 0 is based
on the test statistic
T =
vδˆ1 + (1− v)δˆ3√
v2Var(δˆ1) + 2v(1 − v)Cov(δˆ1, δˆ3) + (1− v)2Var(δˆ3)
,
where the effects, variances and covariance are estimated with the model above. We assume
T to follow approximately the standard normal distribution under the null hypothesis.
2.2.3 Estimation of placebo non-response as a subject characteristic
In reality the placebo non-responce characteristic is an unknown quantity. We propose
here two ways of defining and estimating that characteristic.
Model for placebo non-response prediction: Placebo response can be affected by a num-
ber of factors such as age, gender, severity of disease etc. Therefore, it is appropriate to
create a model that predicts the probability of responding to placebo based on subject’s
characteristics.
We propose to generate a subject’s propensity score of placebo response (or inversely
placebo non-response) based on the subject’s characteristics. A simple model based solely
on baseline outcome measure (and hence on the baseline disease severity) is presented
below.
w(yi0) = pr(Ri = 0|Yi,0 = yi,0); i = 1 : nP
Above Yi,0 is the outcome measure at baseline for subject i, Ri is a response indicator
taking value 0 or 1 (for non-response or response to placebo, respectively) and nP is the
number of Stage I placebo subjects. In practice w(yi0) can be easily estimated with logistic
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regression applied to Stage I placebo subjects data.
Placebo non-response as a characteristic based on trial data: Alternatively, one can
measure subject’s non-response to placebo based on the data observed in Stage I. In general,
each subject can be placed in the Rn space of the n measured characteristics. Since the
characteristics are selected to express placebo non-response (actual change from baseline,
percent change from baseline, disease severity etc.), the subjects with similar degree of
non-response will naturally be closer to each other. And hence the subject’s coordinates
can be used as a measure of non-response. We propose to use K-means clustering to
determine subjects relative positions in the Rn space. K is set to 2 in order to group
‘placebo responders’ and ‘placebo non-responders’ (Figure 2.2).
In this example, two variables are considered for clustering: percent change from base-
line in Stage I and the Stage II baseline. We expect that non-responders would have low
percent change from baseline and high Stage II baseline. The former quality is simply by
definition of non-response, and the latter quality is due to the smaller change in Stage I
and due to inverse relationship of the disease severity and placebo response. These two
variables are likely to be correlated. Therefore, to preserve relative distances and to base
our analysis on the Euclidean distance we propose to compute 2 principal components for
the two measures above. Then, following procedure can be used to determine individual
placebo response measure.
1. Perform K-means clustering (withK = 2) on the 2 principal components. The centers
of clusters, the variability within clusters and the total variability are retrieved from
the analysis.
2. The center-point coordinates (adjusted for within cluster variability) are computed
as follows:
c1 =
m11s21 +m21s11
s11 + s21
c2 =
m12s22 +m22s12
s12 + s22
,
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Figure 2.2: K-means clustering
where c1 and c2 are X and Y center coordinates, m11, m21 are mean X coordinates
of cluster 1 and cluster 2, m12 and m22 - are the mean Y coordinates of the clusters,
s11 and s21 are the standard deviations of the X coordinates, and s12 and s22 are the
standard deviations of Y coordinates.
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3. The distance di to the center-point for subject i is computed as follows:
di = (−1)Ci
√
(p1i − c1)2 + (p2i − c2)2; i = 1 : nP ,
where Ci ⊂ {1, 2} is the cluster (in this example, cluster 1 subjects have higher
change and lower Stage II baseline - responders, and cluster 2 subjects have lower
change and higher baseline at Stage II - non-responders), and p1i and p2i are the two
principal components for ith subject.
4. The subject specific scores are then computed as follows:
wi,k = Φk(di)
where Φk is the CDF function of normal distribution with mean 0 and standard de-
viation k×TSD (TSD is total standard deviation determined in K-means clustering
step). The parameter k regulates values close to the tails of the distribution. Lower
values of k produce the w function that is close in shape to a step-function, and
higher values of k produce function that is close to linear.
This approach can be easily generalized for larger number of measured parameters. The
number of principal components may change accordingly.
Both methods provide us with subject-specific measures of placebo non-response, rang-
ing from 0 to 1. The scores close to 0 correspond to high placebo response and the scores
close to 1 correspond to low placebo response.
2.2.4 Simulation Study
The explicit formulations for power are not trivial in this setting. And, therefore, we used
simulation approach to evaluate statistical characteristics of the proposed method.
A large simulation study was performed to assess characteristics of the weighted re-
peated measure model methods in comparison to the unweighted method proposed by
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Doros at al. The following parameters were fixed based on a recent clinical trial utilizing
SPCD design [21]: The mean and standard deviation of the outcome at baseline were set
to 31 and 5, respectively. Standard deviations of the changes from baseline to the end of
Stage I and Stage II were set to 7. The correlation between baseline and the changes in
both Stage I and Stage II was set to 0.1. Non-response was defined as both change from
baseline to the end of Stage I not in excess of half of the baseline outcome value and an
outcome value at the end of Stage I greater than 16. The non-response rate was set to 0.75.
Mean changes in Stage II among subjects on active treatment in Stage I were assumed to
be 60% smaller than the corresponding changes in Stage I. Stage II attrition was set to
10%.
We considered the following sample sizes: 75, 90, 120, 150 and 300 subjects, with Stage I
randomization 2:1 in favor of placebo, so that at Stage I 25, 30, 40, 50 and 100 subjects were
assigned to an active treatment and twice as many were assigned to placebo. Correlations
between the change in the outcome during Stage I and the change in the outcome during
Stage II were assumed to be the same for all treatment arms and equal to -0.5, -0.4, -
0.3, -0.2, -0.1, 0, 0.1, 0.2, 0.3, 0.4, and 0.5. Treatment effects for power calculations were
controlled by appropriate selection of δ1, δ31 and δ32 (as defined in Figure 2.1). Relating
δ32 = hδ31, we assessed multiple values for parameter h ranging from 0 to 2. The values of
δ1, δ31 and δ32 were set to 0 for assessment of type I error and mean square error (MSE).
For power calculations, the effect sizes in the two Stages were chosen to be equal to 0.3,
0.4 and 0.5 standard deviations of change from baseline.
For each scenario and fixed non-response rate, the parameters δ0, δ01 and δ02 were
calculated, using Monte Carlo methods and the formulas developed in Doros at al. [18] Data
were generated as multivariate normal. For each scenario, we generated 10,000 datasets
that were analyzed using both the proposed weighted methods and the original unweighted
method. The SPCD effect weight v was set to 0.5, based on the ADAPT-A design.[19] All
simulations were ran twice with variance estimated by either restricted maximum likelihood
or using the ‘empirical’ estimator. We report here only results of one set of simulations
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that employed the ‘robust’ method due to similarity of findings. Simulations were run in
SAS 9.2 on a Linux cluster.
2.3 Results
Results from simulations are displayed in Figures 2.3, 2.4 and 2.5. We considered over 1350
scenarios based on different parameter combinations; below we discuss some important
trends.
Type I Error: For all sample sizes, the propensity weighted method has a type I error
that is either lower or about the same as type I error in the unweighted design. This is also
true across all correlation values. The K-means based weighting gives a range of results.
When lower values of k are used, the type I error is slightly inflated across all correlation
values and sample sizes. However, k = 1.5 scenario preserves type I error at least as well
as the unweighted and the propensity weighted methods. (Figure 2.3)
Mean Square Error (MSE): The MSE is consistently the lowest for the propensity
weighted design. This is true for all sample sizes and all correlation values. The K-means
based weighting again gives a range of results. For K-means based design with k of 0.5
and 1.0 the MSE is consistently higher across all correlation values and sample sizes. But
k = 1.5 scenario yields MSE values similar to the unweighted method. (Figure 2.4)
Power: Power was assessed for three effect sizes: 0.3, 0.4 and 0.5 standard deviation.
In all three cases here the effect size was simulated to be the same in responders and non-
responders, i.e. δ31 = δ32. The results are similar for all three cases. Figure 2.5 shows the
power for effect size of 0.5 standard deviation. For propensity weighted design, assessment
shows that when high positive correlation is present between the change in the outcome
during Stage I and the change in the outcome during Stage II, the weighted and unweighted
methods perform similarly. However, with diminishing correlation the weighted method
clearly outperformed the unweighted method for all sample sizes.
For K-means based approach the power is lower in case of high positive correlation.
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Figure 2.3: Type I Error under different scenarios
But in case of low correlation or high negative correlation the method is either similar
or outperforming the unweighted method for all sample sizes. The propensity weighted
method has consistently more power than the K-means based approach.
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Figure 2.4: Mean Square Error under different scenarios
Additionally, we studied the conditions under which the power of the proposed ap-
proaches may be superior or inferior to the power of the unweighted method. In order to
do that, we assessed power under fixed effect size (0.5SD) simulated in non-responders and
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Figure 2.5: Power 0.5SD under different scenarios
varying effect size simulated in responders, holding sample size and correlation fixed. We
set sample size for each case so that for h = 1 the unweighted method yielded 80% power.
Figure 2.6 shows the results of the simulations.
Not surprisingly, when placebo responders demonstrate higher response to drug com-
paring to placebo non-responders (h > 1), the power of the proposed methods tends to
be higher. This is due to the fact that unweighted method effectively assigns zero weight
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Figure 2.6: Power 0.5SD and varying h
to placebo responders. On the other hand, when Stage I placebo responders have lower
response to the drug in Stage II than is the case for Stage I placebo non-responders (h < 1),
the unweighted method generally yields higher power. This would be expected to typically
be the case for illnesses with ‘flooring effect’, such as most mental illnesses.
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2.4 ADAPT-A Trial Example
The proposed methods were applied to ADAPT-A trial data. The individual weights for
Stage II were determined for Stage I placebo subjects via placebo response prediction
model based on the baseline MADRS score and via K-means clustering based on percent
change from baseline in Stage I and Stage II baseline. The Figure 2.7 shows the weight
characteristics for propensity based approach. Panel 1 of the figure shows the weight change
with the baseline measure (a slight jitter was added in order to show all subjects). Some
placebo responders were assigned relatively high weights and some placebo non-responders
were assigned low weights.
The next three panels of the figure show relationship of the weight and the baseline
MADRS measure with main characteristics determining placebo response - the percent
change from baseline and the MADRS score at the end of Stage I. The vertical and hor-
izontal lines represent the defined response criteria (50% decrease and 16 points MADRS
score). The diameter of the dots is proportional to the weight. Panels 2 and 3 show that
those with high baseline scores - namely above 35 points - tended to have smaller change
in Stage I being on placebo. Hence, those with more severe condition tended to have less
placebo response.
Similarly, Figure 2.8 presents weights based on K-means clustering (K = 2, k = 1.5).
The weights assigned to placebo responders are visibly lower. This results in lower effective
sample size and loss of power.
Table 2.1 presents comparison of the estimates of the unweighted repeated measures
model to the proposed method using weighting of the subjects based on propensity to
placebo response and K-means clustering. The difference is quite trivial in this case.
However, several observations can be made. The estimated effect size and standard error of
the unweighted and propensity weighted analyses are most similar. The standard errors of
the K-means based weighted analyses are almost identical to unweighted approach standard
error, but the effect size seems to be higher.
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Figure 2.7: Propensity based weights for placebo responders and non-responders
2.5 Conclusions
Placebo response in the context of SPCD was previously viewed as a binary present or not
present characteristic. In this chapter we considered placebo non-response as a continuous
characteristic that is present, to some degree, in everybody. Given this measure of placebo
non-response, we propose to include it in the analysis of Stage II data in the form of a
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Figure 2.8: K-means based weights for placebo responders and non-responders
weight. With this aim, we proposed a new, placebo non-response weighted method for the
analysis of continuous outcome data in SPCD.
If the weight is a known or easily measured, the estimation of the SPCD effect based on
the weight is relatively straightforward. However, the joint estimation of all model param-
eters including weight is less obvious. The likelihood-based estimation of the parameters
may lead to a problem of non-identifiabilty. This requires further work and in the next
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Table 2.1: ADAPT-A estimates of treatment effect based on the three methods
Method Estimate Standard Error Statistic P-Value
Unweighted Method -0.824 0.991 -0.830 0.407
Weighted Propensity -0.819 0.985 -0.830 0.407
Weighted CDF k=0.5 -0.846 0.990 -0.850 0.394
Weighted CDF k=1.0 -0.867 0.991 -0.880 0.382
Weighted CDF k=1.5 -0.872 0.991 -0.880 0.380
chapter we propose one of the possible methods for the joint estimation. In this chapter
we presented two ad hoc methods of assessing the weight. Depending on the available
data, an analyst can choose to calculate the weights based on either subject characteristics
using the predicted probability of not responding to placebo or based on the trial’s Stage I
outcome data using the K-means clustering approach. Within the K-means based method
we introduced the tuning parameter k. This parameter can be used to change the weight
function from a conservative, such as a step function (mimicking simple classification of
subjects as ‘responders’ or ‘non-responders’ and assigning a weight of 0 to ‘responders’ and
a weight of 1 to ‘non-responders’), to a liberal, such as a linear function.
The proposed approach characteristics are similar to, or in some cases, preferable to
the unweighted method proposed earlier. The MSE reduction suggests improved accuracy
of the effect estimation and the increased power reflects an improved utilization of trial
information. The simulations showed that the propensity-based approach tends to perform
better than the unweighted and the K-means based weighted methods (at least for the
selected values of the tuning parameter k). Nonetheless, it is important to recognize that
the non-response prediction model is only as good as our understanding of the underlying
factors. The issue of the possibly non-additive nature of the placebo effect has to be
considered when constructing of the placebo response prediction model.
It is also important to note that the estimates of the model’s performance characteristics
(type I error, MSE and power) are subject to variability. However, the results of simula-
tions under various assumptions about study parameters consistently demonstrate that the
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weighted methods perform better in the context of a low or negative correlation between
Stage I and Stage II changes. An exception of this is when Stage I placebo responders
respond less robustly to active drug in Stage II than the Stage I placebo non-responders.
In this scenario, such factors as the ‘flooring effect’ must be considered.
The two weight calculation methods described here differ in their use of the response
information. The propensity-based method transforms a binary classification of response to
a continuous one. This use of a binary response classification as the basis for the outcome
of the prediction model may be problematic because of possible misclassification. However,
the method can correct the initial misclassification to some degree based on the subject
characteristics that are included in the prediction model. The K-means based method only
utilizes the knowledge of relationship between a placebo response and the factors used
for clustering, necessary to identify the clusters: ‘responders’ and ‘non-responders’. This
method is somewhat less intuitive and requires knowledge of the relationship. However,
it is less affected by misclassification. Both methods allow for inclusion of various factors
that may potentially help to describe placebo response, such as age, gender, education etc.,
and are relatively easy to implement.
Since the main goal of this chapter was to introduce a new approach for including
placebo response into the analysis of the SPCD data, we chose to limit our comparison to
the unweighted repeated measures model only, as it is methodologically most similar to
our proposed approach. For comparisons of the repeated measures model to the OLS and
SUR methods, we refer the reader to Doros et al. 2013. [18]
In conclusion, an accurate estimate of treatment effect in the presence of a high placebo
response depends on the appropriate use of most, if not all, available information and an
understanding of the placebo response. The method proposed here allows a researcher
running an SPCD trial with continuous outcomes to both include more subjects in the Stage
II treatment effect estimation, and incorporate relevant to placebo response information.
Chapter 3
Placebo Response as Latent Binary Characteristic
32
3.1 Introduction
The question of possible misclassification in SPCD studies was raised in earlier work.
[22] To address the uncertainty around identification of ‘placebo responders’ Rybin et al.
proposed to view placebo response as a continuous characteristic that is to some degree
present in each subject, rather than a binary characteristic. The degree of ‘placebo non-
response’ was used as a measure of subject’s contribution (weight) in estimation of the
treatment effect in ‘placebo non-responders’. The authors proposed the weighted repeated
measure model based on method by Doros et al. [18] The weighting allowed each Stage I
placebo subject to contribute in Stage II effect estimation according to their measure of
non-response. This method introduced the transition area of partial response.
In this chapter we propose a different characterization of placebo response. Suppose all
people are either ‘placebo responders’ or ‘placebo non-responders’. A subgroup of people
(including both ‘responders’ and ‘non-responders’) is affected by a certain disease for which
a certain treatment is being studied. A subset of the diseased is enrolled into a clinical
trial. This clinical trial uses a specific measure to assess the change in the disease. The
measure is specific to the disease and the trial, and by itself may be a suboptimal tool to
measure placebo response as an intrinsic characteristic of a subject. However, because it is
selected to measure success of the treatment, it does give us information about symptom
progression in response to a given treatment (active or placebo). Then, even if the measure
used in the trial is itself a satisfactory measure of placebo response characteristic, there
may be a measurement error.
We assume that this binary placebo response characteristic cannot be observed ac-
curately. We view it as a latent characteristic. We observe the outcome in all subjects
without knowing the actual placebo response status of each subject. Thus, the sample
distribution of observed outcomes can be viewed as an unlabeled mixture of the outcome
in ‘placebo responders’ and in ‘placebo non-responders’, and modeled as a mixture of two
distributions with the placebo response probability as the mixing probability.
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Given SPCD study design restrictions, we can estimate the probability of being a
‘placebo responder’ for each subject receiving placebo. Those assigned to active drug are
also a sample from the mixture of ‘placebo responders’ and ‘placebo non-responders’, but
we are unable to estimate the placebo response probability in these subjects, since we do
not observe them on placebo. Fortunately, this does not present a problem for the SPCD
study analysis, because the classification is used only for the Stage II estimate, and in the
Stage I we use pulled estimate for the mixture components.
For continuous outcome measure it is often reasonable to assume normality. Several
methods for estimation of the parameters of mixture of normal distributions were proposed
to date. Redner and Walker presented a comprehensive summary of existing approaches.
[23] We employ the Expectation-maximization (EM) algorithm shown to be superior to
other methods in some ways despite somewhat slow convergence. [24] The mixing proba-
bility is estimated here based on the likelihood of response, and we do not put any distri-
butional assumptions on it.
In this chapter, we first introduce the problem parametrization, specify the likelihood,
describe parameter and variance component estimation, and define treatment effect within
the proposed model. We then describe the simulation study and present results of the
simulations showing the method performance against the other known methods. Finally,
we present an example of application of this latent characteristic approach to a known
SPCD study.
3.2 Methodology
3.2.1 Placebo response as latent characteristic
Let us suppose we analyze data from an SPCD trial with two stages of equal length. Figure
3.1 shows graphical presentation of the effects in SPCD study with respect to placebo
response characteristic.
Placebo ‘non-responders’ and ‘responders’ are shown in white and striped rectangles.
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Placebo Non−Responders
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Figure 3.1: Sequential parallel comparison design study
The arrows represent outcome progression in different subgroups: δ1 and δ2 are changes in
Stage I placebo group in ‘non-responders’ and ‘responders’; δ3 and δ4 are changes in Stage
I drug group in ‘non-responders’ and ‘responders’; δ11 and δ12 are Stage II changes in
placebo ‘non-responders’ randomizes to placebo and drug; δ21 and δ22 are Stage II changes
in placebo ‘responders’ randomizes to placebo and drug; δ32 and δ42 are Stage II changes in
Stage I drug group patients remaining on active drug. If the placebo response probability is
π, the Stage I treatment effect in overall sample is ∆1 = (πδ4+(1−π)δ3)−(πδ2+(1−π)δ1),
Stage II treatment effect in ‘placebo non-responders’ is ∆NR2 = δ12 − δ11 and Stage II
treatment effect in ‘placebo responders’ is ∆R2 = δ22− δ21. Therefore, for a specified SPCD
weight w, the SPCD treatment effect is the linear combination ∆w = w∆1 + (1−w)∆NR2 .
More precisely, suppose we observe three values of a disease severity measure Y01, Y02
and Y03 at baseline, end of Stage I and end of Stage II, correspondingly. The outcome for
Stage I is defined as change from baseline to the end of Stage I (Y1 = Y02 − Y01), and the
outcome for Stage II is defined as change from the end of Stage I to the end of Stage II
(Y2 = Y03 − Y02).
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Let g1i and g2i be binary indicators for Stage I and Stage II group assignment (placebo
= 0, drug = 1) for subject i. Let Ri = 0 or 1 be an indicator of being ‘placebo responder’ for
subject i. The Ri is an unobserved (latent) characteristic that assumed to follow binomial
distribution Ri ∼ Bin(1, πi), where πi is the probability of placebo response.
Assuming normality, we can summarize the outcome distributions in SPCD study
groups as shown in Table 3.1. Note, that in general the Stage I drug group is a mix-
ture of ‘placebo responders’ and ‘placebo non-responders’, but it is treated here and in the
following text as a non-mixture.
Table 3.1: SPCD Parametrization: Distributions
Treatment Group Stage I Stage II
Drug p11(Y1|Y01) ∼ N(µ11, σ211) p21(Y2|Y1) ∼ N(µ21, σ221)
Placebo Responders p101(Y1|Y01) ∼ N(µ101, σ2101) p201(Y2|Y1) ∼ N(µ201, σ2201)
Placebo Non-Responders p102(Y1|Y01) ∼ N(µ102, σ2102) p202(Y2|Y1) ∼ N(µ202, σ2202)
The means can be further modeled as functions of baseline, preceding change and
group assignment as shown in Table 3.2. Here, b24 and b26 are Stage II treatment effects
in ‘placebo responders’ and ‘placebo non-responders’, correspondingly.
Table 3.2: SPCD Parametrization: Mean functions
Treatment Group Stage I Stage II
Drug µ11 = b01 + b11Y01 µ21 = b02 + b12Y1
Placebo Responders µ101 = b03 + b13Y01 µ201 = b04 + b14Y1 + b24g2
Placebo Non-Responders µ102 = b05 + b15Y01 µ202 = b06 + b16Y1 + b26g2
3.2.2 Expectation-maximization algorithm
Expectation-maximization algorithm (EM algorithm) was introduced by Dempster, Laird
and Rubin in 1977.[24] The algorithm allows making inference in presence of missing or
latent data if the distribution of the latent data can be specified. Suppose data Yo is
observed data, Ym is missing data and Θ is a set of parameters, then the complete data is
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Y = (Yo, Ym) and the joint density can be written as follows.
p(Y |θ) = p(Yo, Ym|Θ) = p(Ym|Yo,Θ)p(Yo|Θ)
and
log(p(Yo|Θ)) = log(p(Yo, Ym|Θ))− log(p(Ym|Yo,Θ))
We can then integrate both sides of the equation over all possible values of missing data
and rewrite the equation as follows.
log(p(Yo|Θ)) =
∫
log(p(Yo, Ym|Θ))p(Ym|Yo,Θ)dYm −
∫
log(p(Ym|Yo,Θ))p(Ym|Yo,Θ)dYm
= Q(Θ)−H(Θ)
It was shown that improvement in Q(Θ) function alone independently of H(Θ) function
would increase the log likelihood of the observed data.
The algorithm begins with initiation of the parameter set Θ = θ(0), computing the
Q-function (expectation step) and then finding an updated parameter set θ(1) given the
initial parameters θ(0) and observed data Yo (maximization step). The expectation and
maximization steps are iterated until convergence of all parameters in the set.
3.2.3 Parameter estimation
The joint distribution of Y1 and Y2 for Stage I drug subjects can be presented as a product
of marginal and conditional distributions.
p(y1i, y2i) = p11(y1i)p21(y2i|y1i)
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The joint distribution of Y1 and Y2 for Stage I placebo subjects can be presented as Gaussian
mixture of ‘responders’ and ‘non-responders’ distributions with mixture parameter π
p(y1i, y2i, Ri) = p(Ri)p(y1i, y2i|Ri) = πRi(1− π)1−Rip(y1i, y2i|Ri)
and
p(y1i, y2i|Ri = 1) = p101(y1i)p201(y2i|y1i)
p(y1i, y2i|Ri = 0) = p102(y1i)p202(y2i|y1i).
Therefore, the full likelihood can be written as follows.
L =
N∏
i=1
[p11(y1i)p21(y2i|y1i)]g1i ×
[
πRi(1− π)1−Ri [p101(y1i)p201(y2i|y1i)]Ri [p102(y1i)p202(y2i|yi1)]1−Ri
]1−g1i
The expected value of response for i-th individual Ri distributed as Bin(1, πi) is πi. There-
fore, after the integration of log likelihood the Q-function takes following form.
Q =
N∑
i=1
g1i log p11(y1i) +
N∑
i=1
g1i log p21(y2i|y1i)+
N∑
i=1
(1− g1i)πi log p101(y1i) +
N∑
i=1
(1− g1i)πi log p201(y2i|y1i)+
N∑
i=1
(1− g1i)(1− πi) log p102(y1i) +
N∑
i=1
(1− g1i)(1− πi) log p202(y2i|y1i)
In general, the response probability for i-th subject at iteration s + 1 can be calculated
from the mixture probability function, and current estimates of the parameters θ(s) and
the placebo response π(s).
π
(s+1)
i =
π(s)p101(y1i|θ(s))p201(y2i|y1i, θ(s))
π(s)p101(y1i|θ(s))p201(y2i|y1i, θ(s)) + (1− π(s))p102(y1i|θ(s))p202(y2i|y1i, θ(s))
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Here, we define the placebo response as a function of subject’s change in outcome while
assigned placebo during Stage I alone. This definition is consistent with the definition of
placebo response in SPCD setting.
π
(s+1)
i =
π(s)p101(y1i|θ(s))
π(s)p101(y1i|θ(s)) + (1− π(s))p102(y1i|θ(s))
Then, the response probability π is calculated as average of individual response probabilities
πi.
π(s+1) =
∑N
i=1(1− g1i)π(s+1)i∑N
i=1(1− g1i)
At each iteration of the EM algorithm the model parameters are estimated. All distri-
bution parameters can be maximized explicitly using Q-function derivatives. Appendix .1
presents the formulations for all model parameters.
The covariance matrix of the parameters can be estimated at each iteration by inverse
of the observed Fisher information matrix Σ = I−1(θˆ), where I(θˆ) = −(∂2Q(θ|Yo)
∂θ2
)θ=θˆ, θ is
a vector of parameters and Yo is observed outcome data. The elements of Hessian matrix
are listed in Appendix .2.
It is important to note that the algorithm does not distinguish between actual response
and non-response, but simply groups the observations and estimates probability of being
in one of the groups. After convergence it is up to analyst to determine which group is
which. It is logical to treat the group with larger Stage I change as ‘placebo responders’.
3.2.4 The definition of treatment effect
The SPCD treatment effect is defined as a linear combination of the Stage I effect estimated
in all subjects and the Stage II effect estimated in ‘placebo non-responders’. The Stage I
treatment effect is constructed from parameters and their variances estimated by EM. The
39
Stage I change in drug group is
µˆ11 = bˆ01 + bˆ11
∑N
i=1 g1iy01i∑N
i=1 g1i
.
And the variance of the Stage I change in drug group σˆ211 is a sum of the elements of
corresponding covariance matrix.
The Stage I change in placebo group is constructed as a mean change of the mixture
as follows.
µˆ10 = πµˆ101 + (1− π)µˆ102
= π
(
bˆ03 + bˆ13
∑N
i=1(1− g1i)y01i∑N
i=1(1− g1i)
)
+ (1− π)
(
bˆ05 + bˆ15
∑N
i=1(1− g1i)y01i∑N
i=1(1− g1i)
)
.
Variance of each mixture component σˆ2101 and σˆ
2
102 is a sum of the elements of corre-
sponding covariance matrix. And the variance of the Stage I change in placebo group is
calculated as follows.
σˆ210 = π
2σˆ2101 + (1− π)2σˆ2102
Therefore, Stage I treatment effect is ∆ˆ1 = µˆ11 − µˆ10 with corresponding variance
Var(∆ˆ1) = σˆ
2
11 + σˆ
2
10.
The Stage II treatment effect in ‘placebo non-responders’ ∆ˆNR2 and its variance are
directly estimated with EM algorithm as bˆ26 and Var(bˆ26).
The SPCD effect weight w is specified. A test for H0 : ∆w = w∆1 + (1 − w)∆NR2 = 0
is based on the test statistic
T =
w∆ˆ1 + (1− w)∆ˆNR2√
w2Var(∆ˆ1) + (1−w)2Var(∆ˆNR2 )
.
We assume T to follow approximately the standard normal distribution under the null
hypothesis.
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3.2.5 Simulation study
The explicit formulations for power are not trivial in this setting. We used simulation
approach to evaluate statistical characteristics of the proposed method.
We conducted a large simulation study to assess performance of the proposed method
against known approaches. The data were generated for three patient groups - Stage I
drug group, Stage I ‘placebo responders’ and Stage I ‘placebo non-responders’ - from three
multivariate normal distributions.
3.2.5.1 General considerations
In the previous chapter, similar to work by Doros et. al. (2013) [18], the outcomes of both
‘placebo responders’ and ‘placebo non-responders’ were assumed to come from the same
distribution. This assumption is relaxed here and it is viewed as a specific case, when the
mixture components are exactly the same. The view of placebo response as a latent binary
characteristic calls for a different way of data simulation.
Specifically, two important points were considered when we generated data for our
simulation study. First point is determining the degree to which ‘placebo responders’
differ from ‘placebo non-responders’ in terms of their mean response. This directly relates
to bimodality and to the degree of means separation in the Stage I outcome mixture.
Second, as explicitly shown by Doros et al., the non-response rate in placebo subjects is a
function of the parameters of their outcome distribution. [18] This fact is important as for
simulating the data to evaluate performance of the analytical methods, as for performing
power calculations for an SPCD study. We will next address each of the two points.
Bimodality of the outcome distribution plays an important role in motivation for mod-
eling the outcome as a mixture of two distributions as opposed to a single distribution; and
it defines the mixture components separation. General bimodality criteria for mixture of
two normal distributions were given by Robertson and Fryer (1969). [25] For a simple case
of mixture of two normal distributions with same variance and mixing probability 0.5, the
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distance between means in excess of 2 standard deviations results in bimodality.
Additionally, the degree to which Stage I change differ between ‘responders’ and ‘non-
responders’ facilitates modeling of the data. Redner and Walker showed that this difference
determines the condition number of the Hessian matrix and hence directly affects the accu-
racy of parameter estimation.[23] A difference of about three standard deviations showed
reasonably small values of the condition number. This corresponds to a good separation
of the mixture components.
To address the second point, suppose that in placebo subjects the distribution of out-
come at baseline and the end of Stage I is a mixture of multivariate normal distributions
with equal covariance (this constraint can be easily removed) and mixing probability π.
p (Y01, Y02) = πp1(Y01, Y02) + (1− π)p2(Y01, Y02)
p1(Y01, Y02) ∼ N
(µ011, µ021),
 σ201 ρσ01σ02
ρσ01σ02 σ
2
02


p2(Y01, Y02) ∼ N
(µ012, µ022),
 σ201 ρσ01σ02
ρσ01σ02 σ
2
02


If placebo non-response is defined as both less than 50% change from baseline and the
outcome measure at the end of Stage I above certain fixed non-response threshold Ψ, then
probability of non-response can be presented as follows.
pNR = P (2Y02 > Y10, Y02 > Ψ) =
=
∫ ∫
2y02>y01,y02>Ψ
(
πp1(y01, y02) + (1− π)p2(y01, y02)
)
dy01dy02 =
= π
∫ ∞
Ψ
(∫ 2y02
−∞
p1(y01|y02)dy01
)
p1(y02)dy02+
+(1− π)
∫ ∞
Ψ
(∫ 2y02
−∞
p2(y01|y02)dy01
)
p2(y02)dy02 =
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= π
∫ ∞
Ψ
Φ
(
2y02 − µ011 − σ01σ02 ρ(y02 − µ021)
σ01
√
1− ρ2
)
p1(y02)dy02+
(1− π)
∫ ∞
Ψ
Φ
(
2y02 − µ012 − σ01σ02 ρ(y02 − µ022)
σ01
√
1− ρ2
)
p2(y02)dy02
= π
∫ ∞
Ψ−µ021
σ02
Φ(a1z + b1)f(z)dz + (1− π)
∫ ∞
Ψ−µ022
σ02
Φ(a2z + b2)f(z)dz =
πE
(
Φ(a1Z + b1)
∣∣∣ Z > Ψ− µ021
σ02
)
+ (1− π)E
(
Φ(a2Z + b2)
∣∣∣ Z > Ψ− µ022
σ02
)
,
where a1 =
2σ02−σ01ρ
σ01
√
1−ρ2
, b1 =
2µ021−µ011
σ01
√
1−ρ2
, a2 =
2σ02−σ01ρ
σ01
√
1−ρ2
, b2 =
2µ022−µ012
σ01
√
1−ρ2
and Z is a standard
normal variable and f and Φ are the density and the CDF of a standard normal distribution.
This implies that, for a given set of parameters in ‘placebo responders’ and a given non-
response rate pNR, we can calculate the Stage I change in ‘placebo non-responders’. This
computation can be performed using Monte Carlo methods.
3.2.5.2 Simulations parameters
The parameters of the distributions were set based on a recent clinical trial utilizing SPCD
design. [21] The mean and standard deviation of the outcome at baseline for all three groups
were set to 31 and 5, respectively. Mean change from baseline to the end of Stage I in
‘placebo responders’ was set to 15. Standard deviations of the Stage I and Stage II changes
in drug group were set to 7, and in each placebo group - to 2 (so that the total variance
in placebo group was similar to the variance in drug group). The correlation between
baseline and the changes in Stage I and in Stage II was set to 0.1. Mean changes in Stage
II were assumed to be 40% smaller than the corresponding changes in Stage I in subjects
remaining on the same treatment. The mixture probability of non-response in placebo
group was set to 0.7. To make the comparisons with other methods (relying of criterion-
based definition of non-response) fair, we defined the parameters of the distribution in
‘placebo non-response’ group such that criterion-based non-response probability was also
0.7. Criterion-based non-response was defined as both change from baseline to the end of
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Stage I not in excess of half of the baseline outcome value and an outcome value at the
end of Stage I greater than 16. We generated the data without missing values.
We considered the following sample sizes: 90, 120, 150, 225, 300, 450 and 600 subjects,
with Stage I randomization 2:1 in favor of placebo, so that at Stage I 30, 40, 50, 75, 100,
150 and 200 subjects were assigned to an active treatment and twice as many were assigned
to placebo. Correlations between the change in the outcome during Stage I and the change
in the outcome during Stage II were assumed to be the same for all treatment arms and
equal to -0.5, -0.4, -0.3, -0.2, -0.1, 0, 0.1, 0.2, 0.3, 0.4, and 0.5. Treatment effects for
power calculations were controlled by appropriate selection of ∆1, ∆
NR
2 and ∆
R
2 . Relating
∆R2 = h∆
NR
2 , we assessed multiple values for parameter h ranging from 0 to 2 to study the
impact of treatment effect difference in placebo response groups. The values of ∆1, ∆
NR
2
and ∆R2 were set to 0 for assessment of type I error and mean squared error (MSE). For
power calculations, the effect size in the two Stages was chosen to be equal to 0.5 standard
deviations of change from baseline in ‘placebo non-responders’.
For each scenario, we generated 5,000 datasets that were analyzed using the proposed
method and three methods relying on criterion definition of placebo response - the OLS
method [6], the repeated measures model [18] and the weighted repeated measures model
using propensity type weighting [22]. For both repeated measures models the robust vari-
ance estimator was used to address possible misspecification of covariance. The SPCD
effect weight w was set to 0.5, based on the ADAPT-A trial design.[19] Simulations were
run in R 3.3.1 and SAS 9.2 on a Linux cluster.
3.3 Results
3.3.1 Overall method performance
In most simulated cases convergence was achieved within 200 iterations of the algorithm.
When running the analyses in R, the elapsed time of running the EM script greatly ex-
ceeded the time of running the lm() function for OLS analysis (0.2 vs. 0.002 seconds
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approximately), but was shorter comparing to running the repeated measures model per-
formed with gls() function (which took about 0.5 seconds).
As expected, with small sample size the estimate of proportion of ‘responders’ was
biased toward 0.5 and with increased sample size the bias decreased. Table 3.3 shows the
estimated response probability for different sample size and correlation between change in
Stage I and change in Stage II. The true response probability was set to 0.3. The degree of
correlation does not seem to influence the estimate as the estimated probability of response
gets close to the true level with large N for all correlation values with approximately the
same rate.
Table 3.3: Estimation of true response probability set at 0.3 by EM
Correlation between Sample size
changes during N = 30 N = 50 N = 75 N = 100 N = 150 N = 200
Stage I and Stage II
ρ = −0.5 0.411 0.380 0.366 0.351 0.330 0.333
ρ = −0.3 0.396 0.381 0.369 0.362 0.326 0.329
ρ = −0.1 0.401 0.378 0.355 0.348 0.341 0.327
ρ = 0 0.409 0.385 0.362 0.357 0.349 0.321
ρ = 0.1 0.409 0.388 0.357 0.340 0.341 0.317
ρ = 0.3 0.407 0.379 0.363 0.346 0.338 0.325
ρ = 0.5 0.398 0.393 0.372 0.348 0.335 0.326
Figure 3.2 shows discriminative ability of the proposed approach based on data simu-
lated with different separation of ‘responders’ and ‘non-responders’. The separation was
measured in terms of standard deviation of change in outcome. Area Under the Curve
(AUC) was calculated based on Wilcoxon rank sum test statistic for each iteration using
estimated probability of response to placebo.
Two observations can be made. First, the discriminative ability increases with separa-
tion. Second, the algorithm takes longer to converge as distributions of ‘responders’ and
‘non-responders’ get closer.
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Figure 3.2: Discriminative ability of the method
3.3.2 Comparison with other methods
The results of simulation study comparing the EM method to the three known methods -
ordinary least squares (OLS), repeated measures model and weighted repeated measures
model - are presented on Figures 3.3, 3.4 and 3.5.
Type I Error: Type I error under different scenarios is presented on Figure 3.3. Clearly,
OLS method gives the largest type I error in excess of 0.05. The EM method and both
repeated measures model methods preserve type I error and show comparable values across
correlation and sample size scenarios.
Mean Square Error (MSE): Figure 3.4 compares the mean squared error of different
methods for simulated data. All four methods show similar MSE for all scenarios.
Power: The power under different scenarios is presented on Figure 3.5. EM has a very
similar to weighted repeated measures model power profile. As expected, OLS has slightly
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Figure 3.3: Type I Error under different scenarios
higher power due to poor Type I error control. And the unweighted repeated measures
model power seems to be influenced by the correlation in the data.
Figure 3.6 shows the MSE in estimation of SPCD effect when the treatment effect
is different in ‘placebo responders’ and ‘placebo non-responders’. The total sample size
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Figure 3.4: Mean Squared Error under different scenarios
was 450 (150:300). The Stage I treatment effect ∆1 and the Stage II treatment effect in
‘placebo non-responders’ ∆NR2 were set to 0.5 SD of Stage II outcome. We varied Stage
II treatment effect in ‘placebo responders’ ∆R2 by changing the value of parameter h in
∆R2 = h∆
NR
2 . Criterion-based methods classify some ‘placebo responders’ as ‘placebo non-
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Figure 3.5: Power under different scenarios
responders’, therefore including some ‘responders’ in estimation of the Stage II treatment
effect in ‘non-responders’. In general, for values of h deviating from 1 (i.e. smaller effect
in ‘placebo responders’ or larger effect in ‘placebo responders’), the OLS method and the
both repeated measures methods demonstrate increased MSE. The EM method shows the
least amount of change in MSE across values of h.
3.3.3 ADAPT-A trial example
We applied the proposed method to the ADAPT-A trial data. For purposes of this analyses
all missing outcome values were imputed using the last observation carried forward (LOCF)
method.
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Figure 3.6: MSE for various Stage II effect in placebo responders
Figure 3.7 presents results of EM algorithm estimation of the treatment effect and the
placebo response probability for three different initial values of parameters. The algorithm
converged after 156 iterations. The estimates of treatment effect at Stage I in all subjects,
at Stage II in ‘placebo non-responders’ and the overall SPCD treatment effect are overall
similar across the four methods used. The EM estimated placebo response rate was 32%
compared to 21% based on the criterion.
3.4 Conclusions
The overall treatment effect in SPCD studies is a combination of the treatment effect in the
full sample and the treatment effect in a subset of patients that do not improve on placebo,
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Figure 3.7: The EM parameter and standard error estimation in ADAPT-A study
called ‘placebo non-responders’. It is important to have a robust way of classification
of a study subjects with respect to their response to placebo. Simple, criterion-based
classification may lead to classification error and bias the inference. The uncertainty about
placebo response characteristic has to be factored in the treatment effect estimation.
In this chapter, we proposed to view the placebo response as a latent binary char-
acteristic. Each person is either ‘placebo responder’ or ‘placebo non-responder’, and the
population is a mixture of the two groups with a certain mixing probability. The goal of
the analysis is estimation of the treatment effect as a combination of the parameters of the
mixture.
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This was done using likelihood based methodology. We modeled the outcome data
as the Gaussian mixture and applied the EM algorithm for estimation of the placebo
response probability and the SPCD treatment effect. We compared this method to the
three methods that were introduced earlier for analysis of SPCD data: the ordinary least
squares method, the repeated measures model and the weighted repeated measures model.
These three methods present a spectrum of assumptions put on the data and the placebo
response definition.
In comparison to the three methods, the EM based approach showed good statistical
properties. It preserved type I error, had similar mean squared error and comparable power.
Simulations showed a specific benefit of the approach for reduction of mean squared error
when treatment effect in ‘placebo responders’ differs from treatment effect in ‘placebo
non-responders’.
This approach can be extremely useful in studies where it is unclear how to define a
robust clinical response to placebo. There are many conditions in medicine, where the
degree of placebo response can vary depending on the outcome measure used and on the
degree of expectations about the outcome. [6] Being able to use a more pragmatic approach
to the definition of placebo response may help investigators in estimating the true effect of
a treatment within an SPCD study.
The use of EM algorithm has some limitations. As we showed above, the small sample
size can potentially bias the estimate of placebo response probability toward 0.5. The
larger the sample size the better the estimation. Performance of the EM algorithm also
improves with clear separation of the means of the mixture. Arguably, when the means are
similar, modeling placebo ‘responders’ and ‘non-responders’ together may be sufficient.
This chapter introduces a new way of thinking about placebo response in SPCD context
as an inherit unobserved quality. This view calls for a methodologically different approach
to analysis of SPCD data. It is especially true when there is a substantial heterogeneity
in response to an active drug between subjects with different placebo response. The la-
tent characteristic approach, described in this chapter, can be successfully used for joint
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modeling of the observed outcome data and the latent placebo response information and
extended further by modeling the response probability.
Chapter 4
Missing Data in Sequential Parallel Design Studies
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4.1 Introduction
Presence of missing data in randomized clinical trials can pose a serious problem. It can
reduce the benefit of randomization and introduce biases in treatment effect estimation. [26]
The initial randomization assures comparability of the treatment groups at the beginning
of the study. However, if missingness occurs during the study, the subset of subjects with
observed data may not any longer be representative of the initial treatment groups and the
study population in general. Because the data are missing, we can only make assumptions
about it. Therefore, the best way of addressing the missingness is to prevent it from
happening by careful consideration at the study design stage and through rigorous follow-
up during the study. Unfortunately, even with the best procedures in place and the most
vigilant follow-up missingness can occur.
Sequential Parallel Comparison Design studies [6, 8–12] are utilized in presence of high
placebo response to estimate placebo response adjusted treatment effect. The design is
effectively used in psychiatric trials and pain medicine where, placebo response rates are
large. Clinical trials conducted in these settings are also known to suffer from high attrition.
Therefore, the issue of missing data is very relevant for SPCD type of trials.
It is important to realize, that missingness in SPCD study can occur sometime during
Stage I. This would directly affect estimation of placebo response and can potentially bias
the treatment effect estimate.
The problem of missing data in Sequential Parallel Comparison Design setting was
studied earlier by Chen (2011) and by Doros (2013). Chen et al. evaluated performance
of several methods under missingness at random (MAR) assumption as defined by Rubin.
[27] It was shown that the repeated measures model performed better than OLS and
SUR methods with single or multiple imputation algorithms used to complete the data.
[17] Doros et al., in context of the repeated measures model use, suggested testing MAR
assumption, and using sensitivity analyses if it does not hold. [18]
In the previous chapter we proposed to use the EM algorithm for joint modeling of the
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outcome and the placebo response in SPCD studies. As the EM algorithm was originally
proposed for making inference in presence of missing data [24], it is natural to use this
methodology to address missingness in the outcome values.
In this chapter, we first introduce factorization of the joint distribution of the outcome
and the missingness mechanism, pose some restrictions for further inference and describe
parameter estimation for the outcome data completed by imputation. We then describe the
simulation study and present results of the simulations showing the method performance
against several known methods. Finally, we present an example of application of the
proposed approach to a known SPCD study.
4.2 Methodology
4.2.1 Framework and definitions
Consider a random variable m = 0 if the outcome Y is observed and m = 1 if it is missing.
We observe Y at most T times. In presence of missingness the model for full set of potential
data is specified by adding a factor for the distribution of m with a parameter ψ. More
precisely, the likelihood has two factors:
f(Y,m|X, θ, ψ) = f(Y |X, θ)f(m|Y,X,ψ),
where Y is an outcome vector of dimension t (1 ≤ t ≤ T ), m is a t×1 vector of missingness
indicators for outcomes, X is a t× p matrix of covariates, and θ and ψ are the respective
parameters of the outcome model and the missingness model.[27]
The missingness likelihood distinguishes observed (O) from missing (M) outcomes as
follows.
f(m|Y,X,ψ) = f(m|Y O, Y M ,X, ψ)
In general, the missingness process can depend on both observed and missing data, in which
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case missingness is not at random (MNAR). We may restrict the probability of missingness
to be independent of the missing outcome missing at random (MAR) or to be independent
of observed and missing outcome all together missing completely at random (MCAR). The
more strict definition of MCAR also includes independence of covariates. In this analysis
we ignore covariates to simplify modeling.
The following equations describe the respective MAR and MCAR factorizations.
f(Y O,m|X, θ, ψ) = f(Y O|X, θ)f(m|Y O,X, ψ)
f(Y O,m|X, θ, ψ) = f(Y O|X, θ)f(m|ψ)
Further under MAR, if parameters θ and ψ are distinct, then the missingness is ignor-
able. Rubin (1976) showed, that under restrictions of ignorable missingness the inferences
about sampling distribution of Y can be made unconditionally on missingness process. [27]
In contrast, when MNAR holds, the estimate of θ depends on m and the missingness is
not ignorable.
This work focuses on dropout or monotone missing data. Dropout occurs at time point
S (1 ≤ S ≤ T ) if mt = 0 for all 1 ≤ t ≤ S, and mt = 1 for all S < t ≤ T . In other words
subjects regularly appear for a period of time and then never appear again. In contrast,
the series of observed repeated measures may have gaps or intermittent missingness. In
general, gaps require a separate missingness model, but to simplify we treat them as MCAR
in this analysis.
4.2.2 Imputation and variance components
While under ignorable missingness the inference can be made based on the observed data,
we can improve efficiency of available information use by imputing missing data based
on the observed data. Orchard and Woodbury (1972) and later Beale and Little (1975)
developed methodology for inference based on data completed with imputation.[28, 29]
Orchard and Woodbury proposed an iterative method of computing mean and variance
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components for multivariate normal outcome distribution in presence of missing data. [28]
Estimation of the variance components is of the most importance, since estimates of means
are unbiased under MCAR or MAR imputation. Under the missing information principle,
the maximum likelihood estimate of variance computed using observed and inputed values
of the outcome is inflated for each imputed value.
More specifically, if we could potentially observe a 1×T vector (t = 1 : T ) of outcomes
Yi for each subject i = 1 : N in the trial, but in reality observe only Y
O
i partition of
the vector, then maximum likelihood estimates of outcome distribution parameters can be
found by cycling through following equations until convergence.
yˆit = E(yit|yoi )
µt =
1
N
N∑
i=1
yˆit
σtk =
1
N
N∑
i=1
((yˆit − µt)(yˆik − µk) + σtk.oi)
σtk.oi = cov(yit, yik|yoi )
where yˆit = yit if yit is observed and linear combination of y
o
i if yit missing, and σtk.oi
is added for every subject i to tk-th observation (1 ≤ t, k ≤ T ) when yit and yik are
missing.[29]
4.2.3 Two-assessment case
Suppose we run a two-stage SPCD trial and observe three values of a disease severity
measure Y01, Y02 and Y03 at baseline, end of Stage I and end of Stage II, correspondingly.
The outcome for Stage I is defined as change from baseline to the end of Stage I Y1 =
Y02−Y01, and the outcome for Stage II is defined as change from the end of Stage I to the
end of Stage II Y2 = Y03 − Y02.
Let g1i and g2i be binary indicators for Stage I and Stage II group assignment (placebo
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= 0, drug = 1) for subject i. Let Ri = 0 or 1 be an indicator of being ‘placebo responder’ for
subject i. The Ri is an unobserved (latent) characteristic that assumed to follow binomial
distribution Ri ∼ Bin(1, πi), where πi is the probability of placebo response.
Suppose all Y1 values are observed, but some of Y2 values are missing. Then, under
ignorability restrictions, we can use maximum likelihood methodology developed in the
previous chapter for complete data case and apply it to this case with missing Stage II
data to make inferences about parameters of outcome distribution. The EM algorithm
procedure can be used for parameter estimation, then the missing data can be imputed
and treatment effect estimated using combination of observed and imputed data. [24] The
variance components can be calculated using Woodbury-Orchard procedure implemented
within EM algorithm iterations. [24, 28, 29]
4.2.4 Multiple-assessment case
In general, disease severity can be assessed not only at baseline and at the end of Stage I
and Stage II but multiple times during each stage. Considering this additional information
can improve quality of imputation of missing outcome values.
To generalize the bivariate case, suppose we run a two-stage SPCD trial and observe
five values of a disease severity measure Y01, Y02, Y03 , Y04 and Y05 at baseline, middle
of Stage I, end of Stage I, middle of Stage II and end of Stage II, correspondingly. The
outcomes for Stage I are defined as change from baseline to the middle and the end of
Stage I (Y1 = Y02 − Y01 and Y2 = Y03 − Y01), and the outcomes for Stage II are defined as
change from the end of Stage I to the middle and the end of Stage II (Y3 = Y04 − Y03 and
Y4 = Y05 − Y03).
As above, let g1i and g2i be binary indicators for Stage I and Stage II group assignment
(placebo = 0, drug = 1) for subject i. Let Ri = 0 or 1 be an indicator of being ‘placebo
responder’ for subject i. The Ri is an unobserved (latent) characteristic that assumed
to follow binomial distribution Ri ∼ Bin(1, πi), where πi is the probability of placebo
response.
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Assuming normality, we can summarize the outcome distributions in SPCD study
groups as shown in Table 4.1. And the means can be further modeled as functions of base-
line, preceding change and group assignment as shown in Table 4.2. Note, that in general
the Stage I drug group is a mixture of ‘placebo responders’ and ‘placebo non-responders’,
but it is treated here and in the following text as a non-mixture.
Table 4.1: SPCD Parametrization Stage: Distributions
Treatment Group Stage I (middle) Stage I (end)
Drug p11(Y1|Y01) ∼ N(µ11, σ211) p21(Y2|Y1) ∼ N(µ21, σ221)
Placebo Responders p101(Y1|Y01) ∼ N(µ101, σ2101) p201(Y2|Y1) ∼ N(µ201, σ2201)
Placebo Non-Responders p102(Y1|Y01) ∼ N(µ102, σ2102) p202(Y2|Y1) ∼ N(µ202, σ2202)
Stage II (middle) Stage II (end)
Drug p31(Y3|Y2) ∼ N(µ31, σ231) p41(Y4|Y3) ∼ N(µ41, σ241)
Placebo Responders p301(Y3|Y2) ∼ N(µ301, σ2301) p401(Y4|Y3) ∼ N(µ401, σ2401)
Placebo Non-Responders p302(Y3|Y2) ∼ N(µ302, σ2302) p402(Y4|Y3) ∼ N(µ402, σ2402)
Table 4.2: SPCD Parametrization: Mean functions
Treatment Group Stage I (middle)
Drug µ11 = α01 + α11Y01
Placebo Responders µ101 = β01 + β11Y01
Placebo Non-Responders µ102 = γ01 + γ11Y01
Stage I (end)
Drug µ21 = α02 + α12Y1
Placebo Responders µ201 = β02 + β12Y1
Placebo Non-Responders µ202 = γ02 + γ12Y1
Stage II (middle)
Drug µ31 = α03 + α13Y1 + α23Y2
Placebo Responders µ301 = β03 + β13Y1 + β23Y2 + β33g2
Placebo Non-Responders µ302 = γ03 + γ13Y1 + γ23Y2 + γ33g2
Stage II (end)
Drug µ41 = α04 + α14Y1 + α24Y2 + α34Y3
Placebo Responders µ401 = β04 + β14Y1 + β24Y2 + β34Y3 + β44g2
Placebo Non-Responders µ402 = γ04 + γ14Y1 + γ24Y2 + γ34Y3 + γ44g2
The joint distribution of Y1, Y2, Y3 and Y4 for Stage I drug subjects can be presented
60
as a product of marginal and conditional distributions.
p(y1i, y2i, y3i, y4i) = p11(y1i)p21(y2i|y1i)p31(y3i|y1i, y2i)p41(y4i|y1i, y2i, y3i)
The joint distribution of Y1, Y2, Y3 and Y4 for Stage I placebo subjects can be presented as
Gaussian mixture of ‘responders’ and ‘non-responders’ distributions with mixture param-
eter π.
p(y1i, y2i, y3i, y4i, Ri) = p(Ri)p(y1i, y2i, y3i, y4i|Ri) = πRi(1− π)1−Rip(y1i, y2i, y3i, y4i|Ri)
and
p(y1i, y2i, y3i, y4i|Ri = 1) = p101(y1i)p201(y2i|y1i)p301(y3i|y1i, y2i)p401(y4i|y1i, y2i, y3i)
p(y1i, y2i, y3i, y4i|Ri = 0) = p102(y1i)p202(y2i|y1i)p302(y3i|y1i, y2i)p402(y4i|y1i, y2i, y3i).
Therefore, the full likelihood can be written as follows.
L =
N∏
i=1
[
p11(y1i)p21(y2i|y1i)p31(y3i|y1i, y2i)p41(y4i|y1i, y2i, y3i)
]g1i
×
[
πRi(1− π)1−Ri
[
p101(y1i)p201(y2i|y1i)p301(y3i|y1i, y2i)p401(y4i|y1i, y2i, y3i)
]Ri×
[
p102(y1i)p202(y2i|y1i)p302(y3i|y1i, y2i)p402(y4i|y1i, y2i, y3i)
]1−Ri]1−g1i
The expected value of response for i-th individual Ri distributed as Bin(1, πi) is πi. There-
fore, after the integration of log likelihood the Q-function takes following form.
Q =
N∑
i=1
g1i log p11(y1i) +
N∑
i=1
g1i log p21(y2i|y1i)+
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N∑
i=1
g1i log p31(y3i|y1i, y2i) +
N∑
i=1
g1i log p41(y4i|y1i, y2i, y3i)+
N∑
i=1
(1− g1i)πi log p101(y1i) +
N∑
i=1
(1− g1i)πi log p201(y2i|y1i)+
N∑
i=1
(1− g1i)πi log p301(y3i|y1i, y2i) +
N∑
i=1
(1− g1i)πi log p401(y4i|y1i, y2i, y3i)+
N∑
i=1
(1− g1i)(1− πi) log p102(y1i) +
N∑
i=1
(1− g1i)(1− πi) log p202(y2i|y1i)+
N∑
i=1
(1− g1i)(1− πi) log p302(y3i|y1i, y2i) +
N∑
i=1
(1− g1i)(1 − πi) log p402(y4i|y1i, y2i, y3i)
At each iteration of the EM algorithm the model parameters are estimated. All distri-
bution parameters can be maximized explicitly using Q-function derivatives. Appendix .3
presents the formulations for all model parameters.
Now suppose all Y1 values are observed, but some of Y2, Y3, and Y4 values are missing.
Then, under ignorability restrictions, we can use maximum likelihood methodology devel-
oped above for imputation of missing outcome values. Then the two-assessment case for-
mulations can be used to estimate treatment effect using combination of observed and im-
puted data [24], and the variance components can be calculated using Woodbury-Orchard
procedure implemented within EM algorithm iterations. [24, 28, 29]
4.2.5 Simulation study
The explicit formulations for power are not trivial in this setting. Similar to previous
chapters, we used simulation approach to evaluate statistical characteristics of the proposed
method.
We conducted a large simulation study to assess performance of the proposed method
against known approaches in presence of missing due to dropout data. The data were
generated for three patient groups - Stage I drug group, Stage I ‘placebo responders’ and
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Stage I ‘placebo non-responders’ - from three multivariate normal distributions, following
Chapter 3 strategy.
4.2.5.1 Mechanism of missingness
To generate missingness under MCAR, MAR and MNAR, we modeled probability of miss-
ingness pmt at each time point t (2 ≤ t ≤ 4) based on the following equation.
log
(
pmt
1− pmt
)
= β0 + β1g
c
t + β2Y
c
t−1 + β3Y
c
t
Parameter β0 was set to model the extent of MCAR and was equal to the logit() of
probability of outcome to be missing at time t regardless of observed or missing data.
Parameters β1 and β2 modeled effect of treatment gt and previously observed outcome Yt−1
on missingness at time t (MAR). And coefficient β3 modeled probability of missingness at
time t as a function of current outcome Yt (MNAR). We centered and standardized the
values of treatment indicator and outcome values in order to model the change per one
standard deviation.
The missingness indicator mt at time t was generated from Bernoully(p
m
t ). Because
only dropout missingness was considered in this work we, first, introduced a gradient of
missingness over time, making it more likely to dropout later in the trial than at the
beginning of the trial, so that probabilities of dropout at time points t = 2, 3 and 4 were
pmt =
1
3p
m
2 ,
2
3p
m
3 and
3
3p
m
4 . And, second, the dropout patterns were forced, so that if
outcome was missing at the end of Stage I (m2 = 1), then it was set to missing at the two
consecutive time points (m3 = 1 and m4 = 1), and if it was missing at the middle of Stage
II (m3 = 1) then it was set to missing at the end of Stage II (m4 = 1).
In all simulations presented in this chapter MCAR missingness was fixed at 10% and
MAR and MNAR missingness varied with missingness probability model parameters. Ad-
ditionally, we studied the influence of missing Stage I outcome by running a set of imputa-
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tions with only Stage II outcome data missing. To make a fair comparison with situation
when outcome was missing at both stages, the amount of data missing at Stage II was held
fixed.
4.2.5.2 Simulation parameters
The parameters of the distributions were set based on a recent clinical trial utilizing SPCD
design. [21] The mean and standard deviation of the outcome at baseline for all three groups
were set to 31 and 5, respectively. Mean change from baseline to the end of Stage I in
‘placebo responders’ was set to 15. Standard deviations of the Stage I and Stage II changes
in drug group were set to 7, and in each placebo group - to 2 (so that the total variance
in placebo group was similar to the variance in drug group). The correlation between
baseline and the changes in Stage I and in Stage II was set to 0.1. Mean changes in Stage
II were assumed to be 40% smaller than the corresponding changes in Stage I in subjects
remaining on the same treatment. The mixture probability of non-response in placebo
group was set to 0.7. To make the comparisons with other methods (relying of criterion-
based definition of non-response) fair, we defined the parameters of the distribution in
‘placebo non-response’ group such that criterion-based non-response probability was also
0.7. Criterion-based non-response was defined as both change from baseline to the end of
Stage I not in excess of half of the baseline outcome value and an outcome value at the
end of Stage I greater than 16.
We considered the total sample size of 300 subjects, with Stage I randomization 2:1 in
favor of placebo, so that at Stage I 100 subjects were assigned to an active treatment and
twice as many were assigned to placebo. Correlations between the change in the outcome
during Stage I and the change in the outcome during Stage II were assumed to be the same
for all treatment arms and equal to -0.3, -0.1, 0.1, and 0.3. All treatment effects were set
to 0 for assessment of type I error and mean squared error (MSE).
For each scenario, we generated 5,000 datasets that were analyzed using the proposed
method and three methods relying on criterion definition of placebo response - the OLS
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method [6], the repeated measures model [18] and the weighted repeated measures model
using propensity type weighting [22]. For both repeated measures models the robust vari-
ance estimator was used to address possible misspecification of covariance. The SPCD
effect weight w was set to 0.5, based on the ADAPT-A trial design.[19] Simulations were
run in R 3.3.1 and SAS 9.2 on a Linux cluster.
4.3 Results
4.3.1 Method performance
Two-assessment case: Results from simulations based on bivariate distribution of outcome
are displayed in Figures 4.1, 4.2, 4.3 and 4.4. The first two figures present performance
of the methods under MAR, and the last two present performance of the methods under
MNAR. For all scenarios treatment effect was set to zero.
Figure 4.1 shows type I error under MAR for different correlation between Stage I and
Stage II outcome measures. Across all simulated scenarios OLS method shows the poorest
control of type I error at about 0.08. Both repeated measures (weighted and unweighted)
control type I error well. The EM method shows slightly inflated type I error.
Mean squared error results under MAR for different correlation between Stage I and
Stage II are shown on Figure 4.2. The EM method results are similar to the weighted
repeated measures model approach. Unweighted repeated measures model is similar to
OLS except for the moderate positive correlation case, when it performs similar to weighted
repeated measures model and the EM. All methods show increased mean squared error at
the both ends of β2 range.
Figure 4.3 shows type I error under MNAR for different correlation between Stage I
and Stage II outcome measures. Across all simulated scenarios OLS method shows the
highest type I error. Both repeated measures (weighted and unweighted) methods and the
EM method show overall similar type I error.
Mean squared error results under MNAR for different correlation between Stage I and
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Figure 4.1: Type I error under MAR (2 assessments): averaged over β1 values
Stage II are shown on Figure 4.4. All four methods perform relatively similar, but the
proposed EM method seems to be consistently at the lower end of the mean standard error
spectrum.
Multiple-assessment case: Results from simulations based on multivariate distribution
of outcome are displayed in Figures 4.5, 4.6, 4.7 and 4.8. The first two figures present
performance of the methods under MAR, and the last two present performance of the
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Figure 4.2: MSE under MAR (2 assessments): averaged over β1 values
methods under MNAR. All scenarios were simulated under H0.
Figure 4.5 shows type I error under MAR for different correlation between Stage I
and Stage II outcome measures. Across all simulated scenarios OLS method shows the
poorest control of type I error at about 0.07 to 0.08. Both repeated measures (weighted
and unweighted) control type I error, but in some cases are too conservative. The EM
method seems to be closes to 0.05, but in the positive correlation cases shows slight type
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Figure 4.3: Type I error under MNAR (2 assessments): averaged over β1 and β2 values
I error inflation.
Mean squared error results under MAR for different correlation between Stage I and
Stage II are shown on Figure 4.6. For all simulated scenarios weighted repeated measures
approach and the EM method perform better than OLS and unweighted repeated measures
model. All methods show increased mean squared error at the both ends of β2 range, but
the EM method seems to be influenced by the extent of missingness the least in case of
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Figure 4.4: MSE under MNAR (2 assessments): averaged over β1 and β2 values
moderate negative correlation.
Figure 4.7 shows type I error under MNAR for different correlation between Stage I
and Stage II outcome measures. Across all simulated scenarios OLS method shows the
highest type I error. Both repeated measures (weighted and unweighted) methods have
the lowest type I error, and the EM method shows slightly higher type I error compared
to the repeated measures methods.
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Figure 4.5: Type I error under MAR (4 assessments): averaged over β1 values
Finally, mean squared error results under MNAR for different correlation between Stage
I and Stage II are shown on Figure 4.8. Methods perform similar for low positive and
low negative correlation values. For moderate positive correlation, OLS produces higher
MSE comparing the the other three methods. On the other hand, for moderate negative
correlation, EM method seems to have lowest MSE.
Comparing to bivariate case, in multivariate case performance of the proposed approach
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Figure 4.6: MSE under MAR (4 assessments): averaged over β1 values
improved in terms of type I error control and the mean squared error. This is possibly due
to use of additional information for imputation of missing data.
4.3.2 Influence of Stage I data missingness
The total SPCD treatment effect is a weighted average of the treatment effect in full
sample measured at the end of Stage I and the treatment effect in placebo ‘non-responders’
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Figure 4.7: Type I error under MNAR (4 assessments): averaged over β1 and β2 values
measured at the end of Stage II. Missing outcome data can affect the treatment effect
estimate differently depending on whether it is missing at the Stage I or at the Stage II.
Missing Stage I outcome data impair estimation of SPCD treatment effect by affecting both
parts of the estimate. First, Stage I outcome is used directly to estimate the treatment effect
in the full sample. Second, Stage I data informs placebo response status determination.
And so, it may directly affect extent of misclassification and, ultimately, the estimate of the
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Figure 4.8: MSE under MNAR (4 assessments): averaged over β1 and β2 values
treatment effect in ‘non-responders’. Figures 4.9 and 4.10 illustrate the impact of missing
Stage I outcome.
Figure 4.9 shows type I error and MSE under MAR for different correlation between
Stage I and Stage II outcome measures. Stage I missing data does not seem to affect type I
error for both low and moderate negative correlation between Stage I and Stage II changes.
However, MSE is elevated when Stage I missingness is present.
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Figure 4.9: Stage I missingness under MAR: results are averaged over β1 values
Under MNAR, the influence of missing Stage I outcome is more prominent. Figure 4.10
shows type I error and mean squared error under MNAR for different correlation between
Stage I and Stage II outcome measures. Type I error is controlled when missingness affects
only Stage II even under MNAR, but with outcome missing at Stage I the type I error is
elevated. Similarly, MSE is increased by introduction of missingness at Stage I.
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Figure 4.10: Stage I missingness under MNAR: results are averaged over β1 and β2 values
4.3.3 ADAPT-A trial example
The proposed method was applied to the ADAPT-A trial data. Of the 225 trial subjects,
221 had at least one efficacy evaluation after randomization and 214 had the end of Stage
I (day 30) evaluation. In the reported primary analysis, using GEE model and data on 221
subjects completed by the last observation carried forward (LOCF) method, the SPCD
treatment effect was -1.51 (95% Confidence Interval -3.11, 0.09).
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We applied several methods to the trial data in order to compare the estimates based
on different approaches to treatment of missing data. The results of the analyses are
summarized in Table 4.3.
Table 4.3: Treatment effect estimates for ADAPT-A trial with missing data
Method N Treatment Effect p-value Missingness
(95% CI) assumption
No Imputation
OLS 214 -1.41 (-3.11, 0.29) 0.105 MCAR
Repeated measures 214 -1.38 (-3.02, 0.26) 0.099 MAR
Weighted repeated measures 214 -1.35 (-2.90, 0.21) 0.089 MAR
EM 214 -1.44 (-3.37, 0.49) 0.144 MAR
Imputation
EM (2 assessments) 214 -1.44 (-3.33, 0.44) 0.133 MAR
EM (4 assessments) 221 -1.65 (-3.36, 0.06) 0.059 MAR
The proposed EM approach using intermediate data gives the highest estimate of the
effect. The estimate is higher than the LOCF estimate reported by ADAPT-A investi-
gators. This is possibly due to the bias toward null, frequently associated with LOCF
imputation, and due to different use of the outcome information. Results of proposed EM
approach based on only information from the end of Stage I and the end of Stage II are
similar to results of other methods with no imputation.
4.4 Conclusions
Missing outcome data pose a serious challenge in analysis of clinical trials. The inference
can be biased if the missingness is informative. But even under non-informative missingness
bias can be present if the estimation does not appropriately use the observed outcome data.
In this chapter we assessed the impact of missing data in context of Sequential Parallel
Comparison Design study. We utilized analysis methodology developed in the previous
chapter, treating placebo response as a latent binary characteristic. We showed, that using
EM algorithm, the missing outcome data can be naturally modeled and imputed along with
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estimation of the placebo response. Generally, proposed method performed reasonably well
compared to the other methods used for SPCD data analysis, especially in case of low or
moderate negative correlation between Stage I and Stage II changes. As we showed earlier,
these may be the expected conditions. [22]
The two-stage SPCD structure presents an additional challenge as the missing data
can play different role if present at different stage. We demonstrated, that if outcome data
are only missing during Stage II of the trail, the proposed method can produce low mean
squared error and control type I error even under MNAR. However, if missingness occurs
during Stage I of the trial, both type I error and MSE suffer.
In this work we used selection model factorization of the likelihood. The pattern-
mixture factorization presents a viable alternative for analysis of incomplete data. [30] This
approach may have and additional benefit of extension for Bayesian sensitivity analysis for
MNAR type of missingness. [31, 32] This may be explored in the future work.
Another area of development is a search for better variance component estimation strat-
egy when using completed with imputation data. Beale and Little proposed an alternative
estimate [29], which can be implemented for SPCD and compared to the Orchard and
Woodbury estimate used here.
In conclusion, there is no perfect way of remedying the missingness at the analysis
stage, and we are always bound by assumptions we have to impose on the missing data.
The proposed method presents a good alternative to the repeated measures method in
context of Sequential Parallel Comparison Design study under MAR. In combination with
placebo response status estimation, the missing outcome imputation can be used in SPCD
trials.
Chapter 5
Summary and Future Studies
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5.1 Summary
The placebo response is present in many clinical trials, and some medical settings seem
to be more susceptible to it than the others. Despite its frequent occurrence, the effect of
placebo response is yet to be fully understood. Unfortunately, the powerful research tool,
that is the trial randomization, does not always eliminate the placebo response bias in the
treatment effect estimate. Therefore, placebo response has to be directly addressed and
studied rather than treated as a nuisance.
It needs to be recognized, that due to our limited knowledge of the mechanisms and
the extent of placebo response, it can not be treated as a measurable characteristic. Our
inference about placebo response has to be probabilistic. And that is the main conceptual
message of this dissertation.
We propose to treat placebo response in our analyses as a random characteristic with
associated uncertainty. We propose to estimate it using collected data and to use that
estimate in our inference about treatment effect. Two analytic strategies are proposed
here. The first strategy is a two-step approach: in the first step we estimate the placebo
response, and in the second step we include the estimate in the outcome model to evaluate
the treatment effect. The second strategy is to model the placebo response and the outcome
jointly, and to estimate the treatment effect from the joint model. Given some limitations,
both strategies show good statistical properties and can be readily implemented. Both
strategies can handle missing outcome data under non-informative missingness.
Based on the simulation studies presented in this dissertation, the second strategy
of placebo response treatment is preferable from statistical point of view. However, the
first, two-step, strategy can be a viable option in situation of poor mixture separation.
The choice between the two proposed strategies has to be driven by our ever increasing
knowledge about placebo response, as we propose the statistical methods to model reality.
Treatment of placebo response as continuous characteristic may better reflect possible
underlying physiological mechanisms of the response to placebo. But the difficulties arise
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in situations of ‘the floor’ or ‘the ceiling’ phenomena. An example of such phenomena is
the super-response.
The super-response to treatment was described in cardiology, oncology and psychiatry.
[33–35] It is thought to be associated with a specific genetic profile. However, the studies
of this subject are limited. Some indirect evidence exists that there may also be the super-
response to placebo. [36] More studies are needed in this area.
We apply this methodology to a specific clinical trial design, that is the Sequential
Parallel Comparison Design (SPCD). The design itself was proposed to address placebo
response by presenting study subjects with a set of evaluations, making it possible to
estimate treatment effect in the full sample and only in those subjects who do not exhibit
placebo response. The design is conducive to further investigations into the nature of
placebo response. One of the less studied, but seemingly important questions is the extent
of placebo response in subjects assigned active treatment. The SPCD modifications, similar
to ones proposed by Ivanova and Tamura (2011) [20], may give us an insight into this
question.
Continuous advancements in clinical trial design and statistical methodology along with
biological studies are essential for our better understanding of placebo response. And the
methods proposed in this dissertation within the SPCD framework can hopefully be one
of the many steps toward that goal.
5.2 Future studies
This dissertation work can be continued in several specific directions. We list these possible
extensions here in the order the methods were presented above.
The first proposed approach to placebo response estimation can be readily extended
by inclusion of different subject characteristics or collected trial data into the estimation
process. That can be done by use of the multivariable logistic regression or multiple
dimension clustering. The careful consideration of the variables to include may be advisable
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to prevent overfitting. The clustering method results were strongly influenced by the choice
of the tunning parameter h, which specified the type of transition from response to non-
response. More work can be done to gain better understanding and to guide the choice of
the parameter in a specific trial setting.
The latent binary characteristic approach can be further developed by considering a
specific distribution of the placebo response. For example, Beta distribution can be con-
sidered. This would provide the way to model the response more comprehensively. It is
expected that the likelihood form may become complicated enough to employ an alterna-
tive to classic EM methodology such as stochastic EM or SEM. [37] The proposed method
works well in case of the good separation of the outcome distribution in ‘responders’ and
‘non-responders’. Future research is needed to quantify the method efficiency for different
degree of separation.
In the treatment of missing data, the algorithm can be further extended to accommo-
date several intermediate measurements of severity if collected during the trial. This may
improve the quality of imputation of missing outcome. The pattern-mixture factorization
with extension for Bayesian sensitivity analysis for MNAR missingness can also be explored
in the future work.[31] Finally, alternative variance component estimation strategies can
be considered. For example, Beale and Little proposed a variance estimate [29], which can
be implemented for SPCD.
Appendix
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.1 Parameter specification in EM algorithm
All model parameters are defined explicitly by differentiating Q-function.
Drug group Stage I:
b01 =
∑N
i=1 g1i(y1i − b11y01i)∑N
i=1 g1i
;
b11 =
∑N
i=1 g1iy01i(y1i − b01)∑N
i=1 g1iy
2
01i
;
σ211 =
∑N
i=1 g1i(y1i − b01 − b11y01i)2∑N
i=1 g1i
Drug group Stage II:
b02 =
∑N
i=1 g1i(y2i − b12y1i)∑N
i=1 g1i
;
b12 =
∑N
i=1 g1iy1i(y2i − b02)∑N
i=1 g1iy
2
1i
;
σ221 =
∑N
i=1 g1i(y2i − b02 − b12y1i)2∑N
i=1 g1i
Placebo responders Stage I:
b03 =
∑N
i=1(1− g1i)πi(y1i − b13y01i)∑N
i=1(1− g1i)πi
;
b13 =
∑N
i=1(1− g1i)πiy01i(y1i − b03)∑N
i=1(1− g1i)πiy201i
;
σ201 =
∑N
i=1(1− g1i)πi(y1i − b03 − b13y01i)2∑N
i=1(1− g1i)πi
Placebo responders Stage II:
b04 =
∑N
i=1(1− g1i)πi(y2i − b14y1i − b24g2i)∑N
i=1(1− g1i)πi
;
b14 =
∑N
i=1(1− g1i)πiy1i(y2i − b04 − b24g2i)∑N
i=1(1− g1i)πiy21i
;
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b24 =
∑N
i=1(1− g1i)πig2i(y2i − b04 − b14y1i)∑N
i=1(1− g1i)πig22i
;
σ2201 =
∑N
i=1(1− g1i)πi(y2i − b04 − b14y1i − b24g2i)2∑N
i=1(1− g1i)πi
Placebo non-responders Stage I:
b05 =
∑N
i=1(1− g1i)(1− πi)(y1i − b15y01i)∑N
i=1(1− g1i)(1− πi)
;
b15 =
∑N
i=1(1− g1i)(1− πi)y01i(y1i − b05)∑N
i=1(1− g1i)(1 − πi)y201i
;
σ202 =
∑N
i=1(1− g1i)(1− πi)(y1i − b05 − b15y01i)2∑N
i=1(1− g1i)(1 − πi)
Placebo non-responders Stage II:
b06 =
∑N
i=1(1− g1i)(1− πi)(y2i − b16y1i − b26g2i)∑N
i=1(1− g1i)(1 − πi)
;
b16 =
∑N
i=1(1− g1i)(1− πi)y1i(y2i − b06 − b26g2i)∑N
i=1(1− g1i)(1 − πi)y21i
;
b26 =
∑N
i=1(1− g1i)(1− πi)g2i(y2i − b06 − b16y1i)∑N
i=1(1− g1i)(1− πi)g22i
;
σ2202 =
∑N
i=1(1− g1i)(1− πi)(y2i − b06 − b16y1i − b26g2i)2∑N
i=1(1− g1i)(1− πi)
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.2 Variance components estimation
The covariance matrices of the parameters are estimated using explicitly specified second
derivatives of Q-function.
Drug group Stage I:
∂2Q
∂b201
= − 1
σ211
N∑
i=1
g1i;
∂2Q
∂b211
= − 1
σ211
N∑
i=1
g1iy
2
01i;
∂2Q
∂b01∂b11
= − 1
σ211
N∑
i=1
g1iy01i
Drug group Stage II:
∂2Q
∂b202
= − 1
σ221
N∑
i=1
g1i;
∂2Q
∂b212
= − 1
σ221
N∑
i=1
g1iy
2
1i;
∂2Q
∂b02∂b12
= − 1
σ212
N∑
i=1
g1iy1i
Placebo responders Stage I:
∂2Q
∂b203
= − 1
σ201
N∑
i=1
(1− g1i)πi; ∂
2Q
∂b213
= − 1
σ201
N∑
i=1
(1− g1i)πiy201i;
∂2Q
∂b03∂b13
= − 1
σ201
N∑
i=1
(1− g1i)πiy01i
Placebo responders Stage II:
∂2Q
∂b204
= − 1
σ2201
N∑
i=1
(1− g1i)πi; ∂
2Q
∂b214
= − 1
σ2201
N∑
i=1
(1− g1i)πiy21i;
∂2Q
∂b224
= − 1
σ2201
N∑
i=1
(1− g1i)πig22i;
∂2Q
∂b04∂b14
= − 1
σ2201
N∑
i=1
(1− g1i)πiy1i;
∂2Q
∂b04∂b24
= − 1
σ2201
N∑
i=1
(1− g1i)πig2i; ∂
2Q
∂b14∂b24
= − 1
σ2201
N∑
i=1
(1− g1i)πiy1ig2i
Placebo non-responders Stage I:
∂2Q
∂b205
= − 1
σ202
N∑
i=1
(1− g1i)(1 − πi); ∂
2Q
∂b215
= − 1
σ202
N∑
i=1
(1− g1i)(1− πi)y201i;
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∂2Q
∂b05∂b15
= − 1
σ202
N∑
i=1
(1− g1i)(1 − πi)y01i
Placebo non-responders Stage II:
∂2Q
∂b206
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi); ∂
2Q
∂b216
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi)y21i;
∂2Q
∂b226
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi)g22i;
∂2Q
∂b06∂b16
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi)y1i;
∂2Q
∂b06∂b26
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi)g2i; ∂
2Q
∂b16∂b26
= − 1
σ2202
N∑
i=1
(1− g1i)(1− πi)y1ig2i
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.3 Parameter specification in EM algorithm (multiple-assessment case)
All model parameters are defined explicitly by differentiating Q-function.
Drug group Stage I (middle):
α01 =
∑N
i=1 g1i(y1i − α11y01i)∑N
i=1 g1i
;
α11 =
∑N
i=1 g1iy01i(y1i − α01)∑N
i=1 g1iy
2
01i
;
σ211 =
∑N
i=1 g1i(y1i − α01 − α11y01i)2∑N
i=1 g1i
Drug group Stage I (end):
α02 =
∑N
i=1 g1i(y2i − α12y1i)∑N
i=1 g1i
;
α12 =
∑N
i=1 g1iy1i(y2i − α02)∑N
i=1 g1iy
2
1i
;
σ221 =
∑N
i=1 g1i(y2i − α02 − α12y1i)2∑N
i=1 g1i
Drug group Stage II (middle):
α03 =
∑N
i=1 g1i(y3i − α13y1i − α23y2i)∑N
i=1 g1i
;
α13 =
∑N
i=1 g1iy1i(y3i − α03 − α23y2i)∑N
i=1 g1iy
2
1i
;
α23 =
∑N
i=1 g1iy2i(y3i − α03 − α13y1i)∑N
i=1 g1iy
2
2i
;
σ231 =
∑N
i=1 g1i(y3i − α03 − α13y1i − α23y2i)2∑N
i=1 g1i
Drug group Stage II (end):
α04 =
∑N
i=1 g1i(y4i − α14y1i − α24y2i − α34y3i)∑N
i=1 g1i
;
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α14 =
∑N
i=1 g1iy1i(y4i − α04 − α24y2i − α34y3i)∑N
i=1 g1iy
2
1i
;
α24 =
∑N
i=1 g1iy2i(y4i − α04 − α14y1i − α34y3i)∑N
i=1 g1iy
2
2i
;
α34 =
∑N
i=1 g1iy3i(y4i − α04 − α14y1i − α24y2i)∑N
i=1 g1iy
2
3i
;
σ241 =
∑N
i=1 g1i(y4i − α04 − α14y1i − α24y2i − α34y3i)2∑N
i=1 g1i
Placebo responders Stage I (middle):
β01 =
∑N
i=1(1− g1i)πi(y1i − β11y01i)∑N
i=1(1− g1i)πi
;
β11 =
∑N
i=1(1− g1i)πiy01i(y1i − β01)∑N
i=1(1− g1i)πiy201i
;
σ2101 =
∑N
i=1(1− g1i)πi(y1i − β01 − β11y01i)2∑N
i=1(1− g1i)πi
Placebo responders Stage I (end):
β02 =
∑N
i=1(1− g1i)πi(y2i − β12y1i)∑N
i=1(1− g1i)πi
;
β12 =
∑N
i=1(1− g1i)πiy1i(y2i − β02)∑N
i=1(1− g1i)πiy21i
;
σ2201 =
∑N
i=1(1− g1i)πi(y2i − β02 − β12y1i)2∑N
i=1(1− g1i)πi
Placebo responders Stage II (middle):
β03 =
∑N
i=1(1− g1i)πi(y3i − β13y1i − β23y2i − β33g2i)∑N
i=1(1− g1i)πi
;
β13 =
∑N
i=1(1− g1i)πiy1i(y3i − β03 − β23y2i − β33g2i)∑N
i=1(1− g1i)πiy21i
;
β23 =
∑N
i=1(1− g1i)πiy2i(y3i − β03 − β13y1i − β33g2i)∑N
i=1(1− g1i)πiy22i
;
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β33 =
∑N
i=1(1− g1i)πig2i(y3i − β03 − β13y1i − β23y2i)∑N
i=1(1− g1i)πig22i
;
σ2301 =
∑N
i=1(1− g1i)πi(y3i − β03 − β13y1i − β23y2i − β33g2i)2∑N
i=1(1− g1i)πi
Placebo responders Stage II (end):
β04 =
∑N
i=1(1− g1i)πi(y4i − β14y1i − β24y2i − β34y3i − β44g2i)∑N
i=1(1− g1i)πi
;
β14 =
∑N
i=1(1− g1i)πiy1i(y4i − β04 − β24y2i − β34y3i − β44g2i)∑N
i=1(1− g1i)πiy21i
;
β24 =
∑N
i=1(1− g1i)πiy2i(y4i − β04 − β14y1i − β34y3i − β44g2i)∑N
i=1(1− g1i)πiy22i
;
β34 =
∑N
i=1(1− g1i)πiy3i(y4i − β04 − β14y1i − β24y2i − β44g2i)∑N
i=1(1− g1i)πiy23i
;
β44 =
∑N
i=1(1− g1i)πig2i(y4i − β04 − β14y1i − β24y2i − β34y3i)∑N
i=1(1− g1i)πig22i
;
σ2401 =
∑N
i=1(1− g1i)πi(y4i − β04 − β14y1i − β24y2i − β34y3i − β44g2i)2∑N
i=1(1− g1i)πi
Placebo non-responders Stage I (middle):
γ01 =
∑N
i=1(1− g1i)(1− πi)(y1i − γ11y01i)∑N
i=1(1− g1i)(1 − πi)
;
γ11 =
∑N
i=1(1− g1i)(1− πi)y01i(y1i − γ01)∑N
i=1(1− g1i)(1− πi)y201i
;
σ2102 =
∑N
i=1(1− g1i)(1 − πi)(y1i − γ01 − γ11y01i)2∑N
i=1(1− g1i)(1− πi)
Placebo non-responders Stage I (end):
γ02 =
∑N
i=1(1− g1i)(1− πi)(y2i − γ12y1i)∑N
i=1(1− g1i)(1 − πi)
;
γ12 =
∑N
i=1(1− g1i)(1− πi)y1i(y2i − γ02)∑N
i=1(1− g1i)(1 − πi)y21i
;
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σ2202 =
∑N
i=1(1− g1i)(1− πi)(y2i − γ02 − γ12y1i)2∑N
i=1(1− g1i)(1− πi)
Placebo non-responders Stage II (middle):
γ03 =
∑N
i=1(1− g1i)(1 − πi)(y3i − γ13y1i − γ23y2i − γ33g2i)∑N
i=1(1− g1i)(1 − πi)
;
γ13 =
∑N
i=1(1− g1i)(1 − πi)y1i(y3i − γ03 − γ23y2i − γ33g2i)∑N
i=1(1− g1i)(1 − πi)y21i
;
γ23 =
∑N
i=1(1− g1i)(1 − πi)y2i(y3i − γ03 − γ13y1i − γ33g2i)∑N
i=1(1− g1i)(1 − πi)y22i
;
γ33 =
∑N
i=1(1− g1i)(1 − πi)g2i(y3i − γ03 − γ13y1i − γ23y2i)∑N
i=1(1− g1i)(1− πi)g22i
;
σ2302 =
∑N
i=1(1− g1i)(1 − πi)(y3i − γ03 − γ13y1i − γ23y2i − γ33g2i)2∑N
i=1(1− g1i)(1− πi)
Placebo non-responders Stage II (end):
γ04 =
∑N
i=1(1− g1i)(1− πi)(y4i − γ14y1i − γ24y2i − γ34y3i − γ44g2i)∑N
i=1(1− g1i)(1 − πi)
;
γ14 =
∑N
i=1(1− g1i)(1− πi)y1i(y4i − γ04 − γ24y2i − γ34y3i − γ44g2i)∑N
i=1(1− g1i)(1 − πi)y21i
;
γ24 =
∑N
i=1(1− g1i)(1− πi)y2i(y4i − γ04 − γ14y1i − γ34y3i − γ44g2i)∑N
i=1(1− g1i)(1 − πi)y22i
;
γ34 =
∑N
i=1(1− g1i)(1− πi)y3i(y4i − γ04 − γ14y1i − γ24y2i − γ44g2i)∑N
i=1(1− g1i)(1 − πi)y23i
;
γ44 =
∑N
i=1(1− g1i)(1− πi)g2i(y4i − γ04 − γ14y1i − γ24y2i − γ34y3i)∑N
i=1(1− g1i)(1− πi)g22i
;
σ2402 =
∑N
i=1(1− g1i)(1− πi)(y4i − γ04 − γ14y1i − γ24y2i − γ34y3i − γ44g2i)2∑N
i=1(1− g1i)(1− πi)
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